

# **Update of Cannabis and its medical use**

**Bertha K. Madras**

**Professor of Psychobiology**

**Department of Psychiatry**

**Harvard Medical School**

**McLean Hospital**

**Alcohol and Drug Abuse Research Program**

**Oaks Building, Rm 342**

**115 Mill Street**

**Belmont, MA 02478**

The author alone is responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of the World Health Organization.

## Contents

---

Preface .....	3
Terminology.....	3
The focus on Cannabis.....	3
Section 1. The cannabis plant and history of medical use .....	4
Section 2. Cannabis chemistry, preparations .....	5
Section 3. Cannabinoid biology, signaling in brain and peripheral tissues.....	6
Section 4. Cannabis toxicity in humans .....	9
Section 5. Dependence, Abuse and Cannabis Use Disorder (CUD).....	14
Section 6. The use of cannabis for medical purposes .....	16
Summary and Conclusions .....	26
References.....	27

## **Preface**

This update of cannabis and its medical use was commissioned by the Secretariat of the Expert Committee on Drug Dependence, Department of Essential Medicines and Health Products, World Health Organization. This document is not a comprehensive review of the literature on cannabis, but a summary of the current status of the field and a framework to incorporate new information as it arises.

## **Terminology**

**Cannabis.** Cannabis is the preferred designation of the plant *Cannabis sativa*, *Cannabis indica*, and of minor significance, *Cannabis ruderalis*.<sup>1</sup> According to the 1961 United Nations Single Convention on Narcotic Drugs, cannabis is defined as “the flowering or fruiting tops of the cannabis plant (excluding the seeds and leaves when not accompanied by the tops) from which the resin has not been extracted, by whatever name they may be designated.”<sup>2</sup> Cannabis resin means “separated resin, whether crude or purified, obtained from the cannabis plant”. These definitions are narrower than the botanical definition and as a consequence, certain parts of the plant are not under international control. The term cannabis will be used instead of *marijuana*, or other names indigenous to local cultures, unless there is a need to refer to a specific phrase, e.g. *medical marijuana ballot initiatives*. Its use for medicinal, ritual or recreational purposes results from the actions of cannabinoids in the cannabis plant. These compounds also produce the unintended adverse consequences of cannabis.

**Cannabinoids.** Cannabinoids are basically derived from three sources: (a) *Phytocannabinoids* are cannabinoid compounds produced by plants *Cannabis sativa* or *Cannabis indica*; (b) *Endocannabinoids* are neurotransmitters produced in the brain or in peripheral tissues, and act on cannabinoid receptors; (c) *Synthetic cannabinoids*, synthesized in the laboratory, are structurally analogous to phytocannabinoids or endocannabinoids and act by similar biological mechanisms.

## **The focus on Cannabis**

The evidence presented on potential medical uses and risks of cannabis in humans focuses on unprocessed, botanical cannabis and not isolated cannabinoids, some of which are medically approved. This is because it has been suggested that the cannabis plant contains chemicals that may be useful for treating illnesses or symptoms. Therefore, it has been advanced that whole plant cannabis could be used for medical purposes. The plant contains at least 750 chemicals, among which are some 104 different cannabinoids.<sup>3,4</sup> The boundaries drawn in this summary between cannabis and isolated cannabinoids is based on the following considerations:

- (a) To avoid confusing terminology;
- (b) The composition, bioavailability, pharmacokinetics and pharmacodynamics of botanical cannabis differs from extracts or purified individual cannabinoids;
- (c) The bioavailability of active cannabinoids in cannabis, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), cannot be predicted because differences in smoking or vapor inhalation vary between users and types of delivery systems. In contrast, a fixed oral dose of a cannabinoid can be quantified in plasma or whole blood samples, yielding relatively predictable results;
- (d) To avoid extrapolating to cannabis conclusions drawn from meta-analyses and primary sources reporting efficacy of purified and medically approved cannabinoid formulations at fixed doses, from randomized controlled trials (RCT). Approved cannabinoids are oral or sublingual spray preparations, whereas cannabis is used predominantly by smoking, inhalation from water pipes or vaporizing, a rapid

form of brain delivery considered a route of administration with higher addiction potential for some drugs, although this principle is not established for cannabis<sup>5, 6, 7, 8</sup> (see Pharmacokinetics, below);

(e) To avoid extrapolation and appropriation of safety data generated from isolated and medically approved cannabinoids (with known doses) to whole plant cannabis, for which there are no guidelines for doses.

A description of cannabinoids that have undergone rigorous approval processes as legitimate medications (with reproducible composition of matter, purity and stability, fixed doses and known pharmacokinetic properties, dose-response efficacy, safety testing, side effect profiles, other criteria), is beyond the scope of this summary. At times, information on specific cannabinoids may be included, if comparisons with botanical cannabis are instructive.

Some cannabinoids have approved therapeutic applications. For instance, the psychoactive cannabinoid, THC (e.g., within Marinol®), has approval for either its anti-emetic and appetite stimulating properties or as a treatment for multiple sclerosis in Canada, Denmark and the United States, and Sativex®, a combination of THC and CBD, has approval for spasticity in 25 countries. Preclinical research has suggested other potential therapeutic applications for non-psychoactive phytocannabinoids. For example, CBD has putative therapeutic applications for treating psychosis, affective and seizure disorders, inflammation, and neurodegenerative disease.<sup>9, 10, 11</sup> Delta-9-tetrahydrocannabinol, another phytocannabinoid, may also be useful for treating epilepsy and obesity.

Botanical cannabis is legally permitted for limited medical use in several countries including 23 states of the United States, in several European countries, Canada and Israel. Approval of cannabis to treat qualifying conditions has typically been based upon small RCTs, surveys, self-reports, *in vitro* or *in vivo* preclinical studies, testimonials or anecdotes delivered, ballot or legislative initiatives, and by advocacy groups.

## **Section 1. The cannabis plant and history of medical use**

An overview by Kalant,<sup>12</sup> provides a historical context and an impression of *déjà vu*, as the medical benefits of cannabis continue to be debated globally. Cannabis grows profusely in most regions of the world, and has been used for millennia to produce fiber and rope. In the early 19th century, Europe was among the last civilizations to encounter the plant, with diverging reasons for using cannabis. In France, the psychoactive effects of cannabis were pursued, whereas in England the use of cannabis focused on medical purposes.<sup>13</sup> Cannabis extracts were listed in the British, and later in the US Pharmacopeia (1850), for sedative and anticonvulsant effects. Within a century, the British and then the US Pharmacopeia removed cannabis listings (1932, 1941, respectively). This was a result of the variable composition of plant preparations, short shelf-life, unpredictable doses, along with becoming overshadowed by newer, more targeted, effective pure drugs prescribed at known and reliable doses.<sup>5</sup> Subsequently, the risks of abuse, intoxication, and other negative consequences of cannabis consumption led to restrictive laws prohibiting the growth, possession and consumption of cannabis.

The movement to revive cannabis as a medicine is driven by multiple factors, many beyond the domain of science.<sup>14</sup> One propellant of the movement is the inadequate relief of current approaches for individuals harboring a number of debilitating chronic diseases or symptoms, including Multiple Sclerosis, Crohn's disease, Alzheimer's disease, cancer, and chronic pain. These and other medical conditions are frequently cited by proponents of cannabis for medical use.

Unresolved and critical questions persist: Is cannabis a safe and effective medicine for one or all of these conditions? For all people of all ages? For chronic use? For medical conditions characterized by cognitive impairment? Before addressing these central questions, it is essential to discuss cannabinoid chemistry and to survey endocannabinoid biology and function, as it is the foundation of claims for cannabis use in numerous medical conditions.

## **Section 2. Cannabis chemistry, preparations**

### **2.1 Known chemistry of *Cannabis sativa***

The principal cannabinoids in the cannabis plant include THC, CBD, and cannabiol (CBN). THC is the primary psychoactive compound, with CBD, a non-psychoactive compound, ranking second. Generally, THC is found at higher concentrations than CBD, unless the ratio is deliberately altered. The known chemical composition of *Cannabis sativa* is constantly changing. New non-cannabinoid and cannabinoid constituents in the plant are discovered frequently. From 2005 to present, the number of cannabinoids identified in the whole plant increased from 70 to 104, and other known compounds in the plant increased from ~400 to ~650.<sup>3,15,16</sup> THC levels are also shifting, as breeding of different strains are yielding plants and resins with dramatic increases in THC content over the past decade, from ~ 3% to 12-16% or higher (w/w or percent THC weight/per dry weight of cannabis) and differing in different countries.<sup>17,18,19,20,21</sup> In some cannabis preparations, THC levels have risen even more radically by using a concentrating process (butane hash oil) that yields levels approaching 80% THC.<sup>22</sup> In an unregulated environment, other factors such as soil quality, bacterial and fungal contamination, the use of herbicides, pesticides, insecticides, water, light, soil availability or quality, temperature, bacterial or viral contamination, animal waste, insects, toxic chemicals, active compounds, heavy metals, bear on cannabis quality.<sup>23</sup>

### **2.2 Dose and dose delivery via different routes (smoking, vaporizers, edibles)**

Cannabis is consumed by various routes, with the most common route smoking,<sup>24</sup> followed by vaporization, and then by the oral route. Cannabis products may be taken by ingesting edibles, sublingual or rectal administration, via transdermal delivery, eye drops and aerosols. However, few studies have documented their pharmacokinetics.

Inhalation by smoking or vaporization releases maximal levels of THC into blood within minutes, peaking at 15-30 minutes, and decreasing within 2-3 hours. Even with a fixed dose of THC in a cannabis cigarette, THC pharmacokinetics and effects vary as a function of the weight of a cannabis cigarette its preparation, the concentration of other cannabinoids, the rate of inhalation, depth and duration of puffs, volume inhaled, extent of breath-holding, vital capacity, escaped smoke and dose titration.<sup>25,26</sup> An extensive comparison of smoke (mainstream: smoke exhaled by a smoker and sidestream: smoke generated from the end of a cigarette) generated by igniting cannabis and tobacco cigarettes, showed marked qualitative similarities in specific compounds (e.g. ammonia, carbon monoxide, hydrogen cyanide, among others), and also significant quantitative differences.<sup>27</sup> The presence, in mainstream or sidestream smoke of cannabis cigarettes, of known carcinogens and other chemicals implicated in respiratory diseases is an important consideration when evaluating the safety and risks associated with cannabis smoking.<sup>28</sup> Lower temperature vaporization of cannabis has been postulated as safer than smoking, as it may deliver fewer high molecular weight components than smoked cannabis.<sup>29</sup> Increasingly, delivery of cannabis to the brain for medical or recreational use is via cannabis vaporization. Heating cannabis at moderate temperatures produces a fine mist of cannabis vapors that are inhaled via electronic cigarettes,<sup>30,31</sup> a delivery method that elicits a similar response while reducing exposure to pyrolytic byproducts. Vaporization reduces the characteristic odor of cannabis smoke, enabling diminished awareness by others

Hashish is a compacted resin of the plant, usually ingested or smoked. Hashish oil, a solvent-extracted liquid, is consumed by smoking or inhalation vaporization or as a food additive.<sup>32</sup> Users report more addictive behaviors and withdrawal symptoms with the high THC levels in this preparation. Oral ingestion from edibles is a slow absorption process and varies with the ingested matrix, as bioavailability is low (10-20%). Nevertheless, this does not result in a loss of pharmacological activity, because the major first-pass metabolite, 11-OH-THC, is also psychoactive. Oral ingestion delays the psychoactive effects to 30-90 minutes, with peaks at 2-3 hours and effects lasting for longer periods of time (4-12 hours), depending on THC levels.<sup>33</sup>

Smoking multiple cannabis cigarettes or chronic long term use leads to higher maximal concentrations, longer duration in blood, and longer biological half-life, compared with smoking a single cigarette or infrequent smoking. Chronic, frequent cannabis smokers' exhibit extended detection windows for plasma cannabinoids, reflecting a large cannabinoid body burden. Lipophilicity of THC accounts for its accumulation after chronic repeated use.<sup>34,35,36,37,38</sup> Metabolic elimination of THC from newly smoked cannabis is much slower after years of heavy cannabis use. When a single 6.8% THC cannabis cigarette was administered to frequent and to occasional users, plasma THC concentrations were significantly higher in frequent smokers than in occasional smokers at most time points from 0.5 to 30 h. Median (range) time of last detection was 3.5 h (1.1 to .30 h) in frequent smokers and 1.0 h (0-2.1 h) in occasional smokers. In chronic heavy (daily) cannabis users, THC can be detected in blood during a month of sustained abstinence. These findings are consistent with THC lipophilicity and time course of persisting neurocognitive impairment reported in recent studies.<sup>39,40</sup>

### **Section 3. Cannabinoid biology, signaling in brain and peripheral tissues**

From an evolutionary perspective the cannabinoid signaling system is ancient, and is found in invertebrates and advanced vertebrate organisms.<sup>41, 42</sup> The endocannabinoid system has four main components:

- (1) G protein-coupled cannabinoid CB1 and CB2 receptors
- (2) Endogenous endocannabinoids that target these receptors, and possibly other receptors
- (3) Enzymes that catalyze endocannabinoid biosynthesis and metabolism
- (4) Mechanisms involved in cell accumulation of specific endocannabinoids

#### **3.1 Cannabinoid receptors: distribution, regulation, function**

The CB1 receptor is expressed in the brain and peripheral tissues. In both locales, it has multiple functions.<sup>43</sup> In the brain, it is the most abundant of the G-protein coupled receptors, and mediates most, if not all the psychoactive effects of THC in cannabis. Its distribution is consistent with the pharmacology of cannabis: CB1 receptors are enriched in the cerebellum (cognition, coordination), hippocampus (learning and memory), cortex (cognitive function, executive function and control, integration of sensory input), basal ganglia (motor control, planning) ventral striatum (prediction and feeling of reward), amygdala (anxiety, emotion, fear), hypothalamus (appetite, hormone levels, sexual behavior), brain stem and spinal cord (vomiting, pain).<sup>44,45,46,47</sup>

CB2 receptors are predominant in the periphery, on immune cells, hematopoietic systems and other locales. There is evidence of CB2 receptor expression in brain.<sup>55,56,48</sup> In the brain, CB2 receptors also modulate the release of chemical signals primarily engaged in immune system functions (e.g. cytokines). CB2 receptors are of considerable interest because all the psychoactive effects of THC in humans can be abolished by selective antagonism of the CB1 receptor, implying that THC activation of CB2 does not produce psychoactive effects.<sup>49</sup> Accordingly, CB2 receptors are a promising target for therapeutics as they may circumvent the adverse effects promulgated by cannabis or THC that engender psychoactive effects via CB1 receptors.

### 3.2 Endocannabinoids and signaling

Endocannabinoids play a fundamental role in regulating pleasure, memory, thinking, concentration, body movement, awareness of time, appetite, pain, and sensory processing (taste, touch, smell, hearing, and sight), and brain development.<sup>56,57</sup> Endocannabinoids acting at CB1 receptors (and possibly CB2 receptors) modulate and “fine-tune” signaling in most brain regions, to enable the brain to adapt to signals generated by multiple sources.

### 3.3 Function of the endocannabinoid system in the brain

Understanding the multiple functions of endocannabinoid signaling in the brain offers insight into the pharmacological effects of cannabis and other exogenous cannabinoids, their therapeutic potential and undesirable adverse effects. An overview by Kalant<sup>50</sup> describes in depth “on demand” endocannabinoid modulation of excitatory and inhibitory synaptic transmission and regulatory functions in the brain.<sup>51</sup>

**3.3.1 Brain development, neurogenesis, psychiatric disorders:** Endocannabinoid signaling is crucial for brain development, and guides neural stem cell survival and proliferation, cell fate decisions and the motility and differentiation of ensuing neuronal and glial cells.<sup>52</sup> Developmental endocannabinoid signaling, from fetus to young adult, may be susceptible to cannabis use during pregnancy and adolescence, possibly affecting brain structure and function. Endocannabinoids and cannabis-altered endocannabinoid signaling may contribute to neuropsychiatric diseases that are of developmental origins and in which modifications to signaling have been observed: autism,<sup>53</sup> schizophrenia,<sup>54</sup> bipolar disorder<sup>55</sup> and depression.<sup>56</sup> The central role of the cannabinoid system in promoting adult neurogenesis in the hippocampus and the lateral ventricles provides insight into the processes underlying post-developmental neurogenesis in the mammalian brain. Both THC<sup>57</sup> and CBD<sup>58</sup> inhibit neurogenesis in adolescent or adult rodent brain, a process of potential relevance to a wide range of cannabis-induced adverse events.<sup>59</sup>

**3.3.2 Neuroprotection:** Cannabinoids and CB1, CB2 receptors display neuroprotective effects in the brain by preventing or decreasing the severity of damage resulting from mechanical, blood flow, or other forms of injury. Genetic ablation of the CB1 receptor exacerbates ischemic stroke,<sup>60</sup> with CB2 agonists providing anti-inflammatory properties and CB1 activation promoting hypothermia. The use of cannabis for this purpose is compromised by psychoactive effects and the development of tolerance to its neuroprotective effects.

**3.3.3 Cannabinoids and sensory function (olfaction, auditory, pain):** The endocannabinoid system contributes to olfactory, auditory and pain sensations. A review of these functions is beyond the scope of this summary but readers are referred to an excellent overview.<sup>61</sup> There is extensive anatomical overlap of the opioid and cannabinoid receptor systems, and it appears probable that functional interactions between them occur in the production of analgesia.

**3.3.4 Appetite and nausea:** A number of nuclei in the medulla are involved in the regulation of appetite and nausea. These nuclei coordinate sensory input from the brainstem, vagal complex, vestibular organs, and peripheral organs. Endocannabinoids and CB1 agonists inhibit vagal fibers to promote eating and CB1 antagonists to decrease or inhibit food intake.<sup>62</sup>

**3.3.5 Sleep:** Endogenous and exogenous cannabinoids, including cannabis and THC, affect sleep patterns.<sup>63</sup> There is poor quality evidence that cannabis or cannabinoids have therapeutic benefit in sleep disorders.<sup>64</sup>

**3.3.6 Affective disorders:** The endocannabinoid system has mood elevating, anti-depressant and anxiolytic effects. The anxiolytic response to cannabis is biphasic, implying that cannabis dosing is a

critical factor in minimizing risk of anxiety, depression and maximizing benefit.<sup>65,66,67</sup> Cannabis at high doses increases the risk for depression or anxiety possibly by down-regulating CB1 receptors.<sup>68,69,70,71</sup>

**3.3.7 Seizure activity:** The endogenous cannabinoid system inhibits seizure susceptibility. Therefore it is unsurprising that exogenous cannabis has antiseizure activity. However, if THC levels are high or cannabis is consumed by susceptible individuals, THC may promote seizures.<sup>72</sup> CBD has therapeutic potential as antiepileptic drug without the psychoactive effects, or potential for pro-seizure activity of whole plant cannabis.<sup>73,74</sup>

**3.3.8 Motor function:** The endocannabinoid system plays a complex role in regulating motor pathways, which conceivably are relevant to symptomatic relief, or to addressing the underlying pathology in a wide range of neurological diseases characterized by motor impairment.<sup>75</sup> CB1 receptors are abundant in brain regions that regulate motor function and coordination, including the basal ganglia, cerebellum. CB1 receptors are down-regulated in several neurological conditions.<sup>76</sup>

**3.3.9 Cognitive functions:** Cannabinoids can both facilitate and degrade learning processes dependent upon the process involved. Endocannabinoids apparently facilitate various forms of learning and memory processes in a number of brain regions. The endogenous cannabinoid system is also implicated in extinguishing learning of aversive situations. On the other hand, THC and cannabis decrease working memory, apparently by actions in the hippocampus, a brain region critical for learning and memory. The memory decrements induced by THC or cannabis resemble hippocampal lesions. These impairments may result from suppression of glutamate release in the hippocampus, which is responsible for the establishment of synaptic plasticity.<sup>77,78,79</sup>

### **3.4 Function of the endocannabinoid system in peripheral tissues**

Endocannabinoid signaling systems are found nearly ubiquitously in the peripheral tissues, with their distribution possibly accounting for the myriad of effects and potential medical applications of cannabinoids. This summary is based on a recent review.<sup>80</sup>

**3.4.1 Gastrointestinal (GI) tract:** CB1 and CB2 receptors are highly expressed on enteric nerves and on enteroendocrine cells (CB2) throughout the intestinal mucosa, on immune cells (CB1 and CB2), and enterocytes (CB1 and CB2). Many gut functions are regulated by endocannabinoids critical for central nervous system (CNS) control of its metabolic and homeostatic functions.

**3.4.2 Cardiovascular system:** CB1, CB2, endocannabinoids and their enzymes are present in cardiovascular tissues and may contribute to the development of common cardiovascular disorders. An acute action of cannabis is mild tachycardia, with increases in cardiac output and increased myocardial oxygen requirement.

**3.4.3 Liver:** Cannabinoid receptor expression is normally low in liver, with CB1 and CB2 receptors acting in opposite directions: CB2 receptors mediate several biological functions in various types of liver cells, and CB1 blockade contributes to beneficial metabolic effects. CB1 expression increases in pathological states, promoting fibrogenesis, steatosis, and cardiovascular complications of liver disease. In contrast, CB2 is protective, reducing these indices of liver dysfunction.

**3.4.4 Immune System:** Endocannabinoids modulate the functional activities of immune cells, largely through CB2 receptors, providing novel targets for therapeutic manipulation.<sup>81</sup>

**3.4.5 Muscle:** Endocannabinoid signaling (largely through CB2 receptors) contributes to regulating energy metabolism in muscle and the formation of new muscle fibers.



**3.4.6 Reproductive System:** Endocannabinoid signaling, primarily mediated by the CB2 receptor regulates all critical stages of pregnancy and affects pregnancy events. Signaling is also involved in the preservation of normal sperm function, and thus male fertility.

**3.4.7 Skin:** Endocannabinoid signaling, through both CB1 and CB2, is involved in regulating skin functions such as proliferation, differentiation, cell survival, immune responses and suppressing cutaneous inflammation. Exogenous modulators of the receptors could clarify the role of the endocannabinoid system in hyperproliferative skin conditions, allergic and inflammatory skin diseases.

**3.4.8 Other organs:** The role of endocannabinoid signaling in respiratory tract and urinary system remains unclear, but there is preliminary evidence that CB1 and CB2 receptors may contribute to kidney disease.

## **Section 4. Cannabis toxicity in humans**

The primary risks of cannabis consumption have been discovered by investigating users of cannabis for recreational purposes. Few studies have reported on long term consequences of cannabis if used for medical purposes. Cannabis engenders acute pharmacological effects, longer term health risks for the brain, body and behavior, and public safety concerns.

### **4.1 Cannabis and the central nervous system (CNS)**

#### **4.1.1 Cognition and coordination.**

Crean et al. (2011) reviewed a broad spectrum of cognitive functions designated as executive functions<sup>82</sup> and identified studies that reported that attention, concentration, decision-making, impulsivity, inhibition (self-control of responses), reaction time, risk taking, verbal fluency and working memory were impaired acutely in a dose-dependent manner, although these effects were not consistently observed.

*Acutely*, cannabis impairs several components of cognitive function, with the most robust effects on short-term episodic and working memory, planning and decision-making, response speed, accuracy and latency.<sup>83</sup> Some studies also report increased risk-taking and impulsivity.<sup>84</sup> Less experienced cannabis users undergo stronger intoxicating effects on attention and concentration than those with established drug tolerance. Acutely, cannabis also impairs motor coordination, interferes with driving skills and increases the risk of injuries. Evidence suggests recent smoking is associated with substantial driving impairment, particularly in occasional smokers,<sup>85</sup> with implications for work in safety-sensitive positions or operating a means of transportation, including airplanes. Complex human/machine performance can be impaired as long as 24 h after smoking a moderate dose of cannabis and the user may be unaware of the drug's influence.<sup>86</sup>

*Recently abstinent cannabis users* (7 hours to 20 days) may experience impairment in attention, concentration, inhibition and impulsivity during the period in which THC and its metabolites are eliminated.<sup>87</sup> The greatest residual deficits in executive function are found following prolonged use of cannabis. In real world situations, in the context of work and everyday life, cannabis use is associated with impaired cognitive function, mood, lower alertness, and slower response. Users also experienced working memory problems at the start, and psychomotor slowing and poorer episodic recall at the end of the working week, possibly 'hangover'-type effect which may increase with frequency of use. The results demonstrate the importance of testing within the context and routine of everyday life.<sup>88</sup>

*Cannabinoids persist even after one month*, and are detectable in blood of chronic daily cannabis smokers during sustained abstinence.<sup>89</sup> Cannabis continues to impair executive functions, with the chronic, heavy

cannabis users showing the most enduring deficits. Decision-making, planning, concept forming are the most prominent and durable deficits, but verbal fluency (information retrieval from memory) may or may not persist at this point.

**4.1.2 Imaging techniques:** A window into the brain of cannabis users can be accessed by various techniques that can assess measurement (MRI), neurochemistry (PET imaging), connectedness or “connectome” (diffusion tensor imaging), function (fMRI), and metabolism (MRI spectroscopy). A number of studies have shown differences in the brains of heavy cannabis users and non-users.<sup>90</sup> Further descriptions of brain changes are provided in the Section 4.3.2. *Adolescence*. Intriguingly, a recent study concludes that cannabis use conceivably is attributable to pre-existing, predispositional differences in the brains of users compared with non-users.<sup>91</sup>

**4.1.3 Psychosis and Schizophrenia:** The strong association between cannabis use and psychosis or schizophrenia has been recognized for over two decades, in at least four ways: (1) cannabis produces a full range of transient schizophrenia-like positive, negative, and cognitive symptoms in some healthy individuals. The induction of psychosis by cannabis was originally reviewed by Warnock in 1903<sup>92</sup> and substantiated subsequently;<sup>93,94</sup> (2) in those harboring a psychotic disorder, cannabis may exacerbate symptoms, trigger relapse, and have negative consequences on the course of the illness;<sup>95</sup> (3) susceptible individuals in the general population develop a psychotic illness with heavy cannabis use, which is associated with age of onset of use, strength of THC in cannabis, frequency of use and duration of use;<sup>96,97</sup> (4) cannabis use is associated with lowering the age of onset of schizophrenia.<sup>98</sup> It is likely that cannabis exposure is a “component cause” that interacts with other factors to precipitate schizophrenia or a psychotic disorder, but is neither necessary nor sufficient to do so alone.<sup>99</sup> Symptoms of schizophrenia increase with cannabis use and strength. The magnitude of the symptoms is associated with amount used and frequency of use. In individuals with an established psychotic disorder, cannabis can exacerbate symptoms, trigger relapse of the disorder, and have negative consequences on the course of the illness.<sup>100,101</sup>

## 4.2 Harmful effects of cannabis in peripheral tissues

An overview of the harmful effects of cannabis was recently published, and forms the basis of some comments below.<sup>102</sup>

**4.2.1 Pulmonary disease and lung cancer:** After adjusting for tobacco use, chronic cannabis use is associated with an increased prevalence of symptoms of chronic bronchitis, and is compatible with injury and inflammation involving the central airways,<sup>103</sup> based on widespread endoscopic and microscopic evidence of injury and inflammation involving the central airways of habitual smokers of cannabis. These include loss of ciliated epithelium and replacement by mucus-secreting goblet cells, the frequency and severity of which were comparable to that of smokers of tobacco alone.<sup>104, 105</sup> What is less clear is the impact of chronic cannabis use on lung function. In the past, as cannabis has been consumed less frequently and as current daily users in the United States among college age students is at its highest levels in three decades),<sup>106</sup> a recent longitudinal study of occasional and low cumulative cannabis users may not be relevant to current patterns of daily use. This study found that cannabis use was not associated with adverse effects on pulmonary function.<sup>107</sup> Cannabis smoke does not appear to contribute to chronic obstructive pulmonary disease nor are its carcinogenic effects clear at the present time. Low levels of cannabis exposure do not appear problematic but regular cannabis smokers are more likely to harbor chronic bronchitis and increased rates of respiratory infections and pneumonia.<sup>108</sup>

**4.2.2 Vascular conditions:** Cannabis use is also associated with vascular conditions that increase the risks of myocardial infarction, stroke, and transient ischemic attacks during cannabis intoxication.<sup>109</sup>

**4.2.3 Cannabis and carcinogenic potential:** One concern of the use of cannabinoids, particularly inhaled cannabis, is carcinogenic potential. There is currently no consensus on whether cannabis use is associated with overall cancer risk. This section summarizes systematic reviews of the literature.<sup>110, 111, 112, 113</sup> Cannabis smoke is carcinogenic in rodents and mutagenic in the Ames test (a cancer test performed for candidate medications in rodents, before drug testing in humans). Cannabis smoke contains several of the same carcinogens as tobacco smoke, at up to 50% higher concentrations and with three times the tar per cigarette. Respiratory mucosa exposed to chronic cannabis smoke shows pre-neoplastic histological and molecular changes. Despite this *in vitro* and *in vivo* evidence, there is no strong correlation between cannabis use and the development of human cancers. For example the link between head and neck squamous cell carcinoma (HNSCC) risk and cannabis is inconsistent. Three studies have found a statistically significant 2.6-fold increased risk of HNSCC in cannabis users compared with controls when adjusted for cannabis dose, duration of use, and confounding variables such as alcohol or tobacco use. Similarly, heavy cannabis smokers in Northern Africa had a 2.62 increased risk for nasopharyngeal carcinomas. At this point the majority of studies do not support conclusions that smoked cannabis is strongly associated with an increased risk of head and neck cancers, once tobacco and alcohol intake are controlled.<sup>114</sup>

A recent review of 34 epidemiologic studies on upper aerodigestive tract cancers, lung cancer, testicular cancer, childhood cancers, all cancers, anal cancer, penile cancer, non-Hodgkin lymphoma, malignant primary gliomas, bladder cancer, and Kaposi sarcoma studies did not appear to support an association of lung cancer with cannabis use, possibly because of the smaller amounts of cannabis regularly smoked compared with tobacco. For other cancer sites, there is still insufficient data to make any conclusions. As cannabis use rates may change, well-designed studies on the association between cannabis use and cancer will be warranted.<sup>115</sup>

However, a pooled analysis of three studies of active male cannabis smokers in North Africa found that the risk for developing lung cancer was increased 2.4 times, but this heightened risk could be confounded by tobacco smoking.<sup>116</sup> A case controlled study of patients with lung cancer under 55 years of age in New Zealand found an 8% increased risk for each joint-year (one joint/day/year) of cannabis use. This effect persisted only in the highest tertile of cannabis use (>10.5 joint-years of exposure) when adjusted for tobacco use.<sup>117</sup>

With cannabis use, there is a trend towards increased non-seminoma testicular germ cell tumors, especially among those who smoke cannabis at least weekly,<sup>118</sup> prostate cancer (3-fold risk), and cervical cancer (1.4 fold risk). The incidence of oropharyngeal and oral tongue cancers has increased over the last 20 years. In a pooled analysis of nine case-control studies from the United States and Latin America, ever cannabis smokers had an elevated risk of oropharyngeal and a reduced risk of oral tongue cancer. The risk of oropharyngeal cancer remained elevated among never tobacco and alcohol users. The risk of oral tongue cancer was reduced among never users of tobacco and alcohol. These results suggest that the association of cannabis use with head and neck carcinoma may differ by tumor site, with both possible pro- and anticarcinogenic effects of cannabinoids. Additional work is needed to rule out various sources of bias, confounds and misclassification of cannabis exposure.<sup>119</sup>

A US study of health maintenance organization members found an increased risk of malignant primary gliomas in people who smoked cannabis once per month or more, but found no dose-response relationship.<sup>120</sup> Smaller studies have implicated cannabis use in the development of bladder cancer and testicular germ cell tumors. The reasons for the great heterogeneity in epidemiologic studies correlating cannabis use and cancer may be related to difficulties in quantifying cannabis use, unmeasured confounders in the cases or controls, and variable expression of cannabinoid receptors in target tissues. Overall, smoked cannabis is associated with a slightly elevated risk for certain cancers.

**4.2.3 Fertility:** *In vivo* and *in vitro* studies have shown that cannabis may disrupt the hypothalamus-pituitary-gonadal axis, spermatogenesis, and sperm function (motility, capacitation, acrosome reaction).<sup>121</sup>

**4.2.4 Cannabis hyperemesis syndrome:** Cannabis has antiemetic properties, one indication for its use medicinally. However, a number of cases of cannabis-induced hyperemesis have been reported. This is a paradoxical clinical syndrome of the gastrointestinal tract and brain which has been designated the title 'Cannabis Hyperemesis Syndrome'. Patients exhibit a triad of symptoms: cyclic vomiting, chronic cannabis use, and compulsive hot water bathing, attributable to heavy cannabis use.<sup>122,123</sup>

**4.2.5 Cannabis, emergency department mentions, mortality:** As cannabis use rises, emergency department mentions from 2004-2011, for cannabis alone or in combination with other drugs, increased substantially. As examples, it represents 36% of all illicit drug mentions in the U.S and 31% in an urban emergency department in Switzerland.<sup>124, 125</sup> In a consortium of 16 sentinel centers across Europe reporting acute drug toxicity presentations in emergency departments, cannabis ranked third among drugs after heroin and cocaine.<sup>126</sup> It has also been reported that cannabis is a small, but increasing burden on emergency services in Australia.<sup>127</sup> The mortality of patients with a cannabis use disorder is also of concern.<sup>128</sup>

### 4.3 Cannabis during development: the adolescent and prenatal periods

**4.3.1 Fetus:** It is challenging to fully clarify the role of cannabis in fetal development, given the range of potentially confounding variables associated with cannabis use during pregnancy (tobacco, alcohol, nutrition, psychology). Nevertheless, accumulating evidence suggests that prenatal exposure may interfere with normal development and maturation of the brain. Children exposed to cannabis *in utero* demonstrate impaired attention, learning and memory, impulsivity and behavioral problems and higher likelihood of using cannabis when they mature.<sup>129,130,131,132,133,134,135</sup> Human research in this domain is still limited, and contrasts with nicotine or alcohol research.

#### 4.3.2 Adolescence

- Vulnerability of the developing brain

Accumulating evidence reveals that regular, heavy cannabis use during adolescence is associated with more severe and persistent negative outcomes than use during adulthood. The adolescent brain may be more vulnerable to cannabis than adults, and early initiation of heavy use may disrupt the trajectory of normal brain development. Heavy or regular adolescent cannabis users manifest a range of cognitive deficits, including impairments in attention, learning, memory, and response perseveration. These deficits are similar in adults but in adolescents, they are more likely to persist and may only recover after longer periods of abstinence.<sup>136</sup> Earlier onset users show greater impairment in cognitive domains, including learning and memory, attention and other executive functions.<sup>137,138</sup> Decrements in cognitive function are correlated with initiation of cannabis use during adolescence.<sup>139</sup>

A recent large-scale longitudinal study followed a large cohort from childhood to age 38, and assessed neuropsychological functioning at multiple time points. It revealed that adolescents who used cannabis weekly or harbored a Cannabis Use Disorder (CUD) before the age of 18, showed larger neuropsychological decline, and I.Q. reduction than those who became dependent during adulthood. The results are consistent with cross-sectional findings in adult populations, and reinforce the conclusion that sustained abstinence may not enable cognitive functional recovery, if use was initiated during adolescence. A subsequent re-analysis showed that socioeconomic differences did not account for the sustained loss of I.Q.<sup>140,141</sup>

Brain imaging has generally revealed changes in brains of adolescents or adults who initiated cannabis during adolescence.<sup>142,143,144</sup> Cannabis users have smaller whole brain and hippocampus, reduced cortical

grey matter and insular cortical thickness<sup>145,146</sup> that is associated with level of use. Some studies found correlations between brain changes and deficits in learning and memory.<sup>147</sup> Age of onset of cannabis use apparently is not as important in hippocampal shrinkage, compared with amount and frequency of use.<sup>148</sup> Changes in cortical volume may predate and predispose individuals to use cannabis, but not in hippocampus.<sup>149</sup> This region is vulnerable to heavy cannabis use, regardless of age.

- Education and cognition

The interaction between cannabis use and education is complex. In several countries, cannabis use is high among high school and college students (e.g. Australia, US, Canada). Because it impairs learning and memory during, and for days after use, with cumulative effects (see above), learning in a school environment may be compromised for a considerable period during the school year.<sup>150</sup> Cannabis use is associated with poor grades and with high drop-out rates,<sup>151</sup> with those dropping out of school engaging in high rates of frequent cannabis use.<sup>152</sup> Environmental and other risk factors add to the complexity of this association.<sup>153</sup> A longitudinal study showed that early initiation of heavy cannabis use is associated with lower income, lower college degree completion, greater need for economic assistance, unemployment, and use of other drugs.<sup>154,155,156</sup> Another longitudinal study, based on student self-reports, teacher ratings and high school dropout records, showed that cannabis is not an isolated or benign event in the life of adolescents but part of an overall problem behavior syndrome.<sup>157</sup>

- Psychosis and Schizophrenia

Research has shown an association of early age of onset of cannabis use to earlier onset of schizophrenia and higher prevalence of psychosis, including mania.<sup>158, 159, 160, 161, 162</sup> The emergence of psychotic symptoms apparently is dose-dependent with more robust symptoms as use and frequency escalate. Some have questioned the association of cannabis use to adverse outcomes in adolescents, claiming either no effects, or environmental components as the underlying risk factor.<sup>163,164</sup>

- Use of other drugs

Surveys in France, the United States, Australia, have shown that the prevalence of a substance use disorder, for drugs other than cannabis, is higher in adolescents who initiate cannabis use, and as a function of age of initiation.<sup>165,166,167</sup> This pattern has been observed in controlled twin studies, in which one pair initiated cannabis use prior to the age of 17 and the other did not.<sup>168,169</sup>

- Bone

Endocannabinoid signaling regulates bone elongation and remodeling by modulating bone cell proliferation, communication between cells, and neuronal control of bone remodeling. In view of THC's profound effects on murine bone growth, this may be relevant to adolescents who consume cannabis during a rapid phase of growth.

#### 4.4 Cannabis and society

Cannabis engenders many consequences to society, which are beyond the scope of this overview. Below is a summary of several adverse consequences.

**4.4.1 Cannabis and driving.** Cannabis impairs driving ability and confers a higher risk for motor vehicle accidents. In experimental settings, cannabis impairs psychomotor skills and cognitive functions associated with driving, including vigilance, time and distance perception, lane tracking, motor coordination, divided attention tasks, and reaction time.<sup>170</sup> Drivers may attempt to compensate by driving more slowly and increasing their following distance. On highways, cannabis is the most frequently reported illicit drug in connection with impaired driving and accidents, including fatal accidents. In the US, (2013), 62.6% of fatally injured drivers were tested for drugs and more than one-third (34.7%) were positive for cannabis.<sup>171</sup> In other countries some attribute increased roadside accidents to

cannabis.<sup>172,173,174,175</sup> The use of cannabis in combination with alcohol increases the risk of impairment more than use with either drug alone as the effects were additive.<sup>176</sup>

**4.4.2 Cannabis, employment, the workplace.** The effects of cannabis use on cognition in the context of work and everyday life, or whether off-site cannabis use endangers a worker or his colleagues while at work, has not been systematically investigated. One study that examined association between cannabis use and cognitive performance, mood and human error at work found that cannabis use was associated with impairment in both cognitive function and mood, though cannabis users self-reported no more workplace errors than controls. Users also displayed lower alertness, slower response organization, working memory problems at the start, and psychomotor slowing and poorer episodic recall at the end of the working week. Subtle effects on cognitive function may be exacerbated with fatigue or work-related demands.<sup>177</sup> During an economic downturn, cannabis use was recently shown to increase unemployment among users.<sup>178</sup> Combined with alcohol, vaporized cannabis yields higher maximum concentrations of blood THC (than without alcohol) detected 8.3 hours later, possibly explaining why performance is more impaired if cannabis is combined with alcohol in this manner.<sup>179,180,181</sup>

There is ample evidence indicating that neurocognitive impairment from cannabis persists from hours to weeks. A return to a non-intoxicated state does not ensure a full return of neurocognitive function in the workplace.<sup>182</sup> In a summary of the dilemmas that cannabis for medical use has created for the workplace, it was pointed out that ensuring safety of workers who are under the influence or who recently consumed cannabis is not possible.<sup>183</sup>

**4.4.3 Cannabis and advanced education.** Several studies have shown that cannabis use can adversely affect academic achievement among adolescents. These are reviewed in Section 4. Cannabis use during college can be a barrier to academic achievement. A large longitudinal cohort study of college students showed that frequency of cannabis use was a significant factor in poor class attendance, lower grades, and longer time to graduate from college.<sup>184,185</sup> A significant proportion of cannabis-using college students meet diagnostic criteria for cannabis use disorder (CUD), and even in the absence of CUD disorder, users appear to be at risk for potentially serious cannabis-related problems. The prevalence of CUD among a sample of college students at one university was relatively high (9.4%), and was 24.6% among past-year cannabis users. Among the most prevalent cannabis-related problems, cannabis users reported concentration problems (40.1%), driving while high (18.6%), missing class (13.9%), and placing oneself at risk for physical injury (24.3%) even among those who did not endorse a CUD criteria.<sup>186</sup>

## **Section 5. Dependence, Abuse and Cannabis Use Disorder (CUD)**

### **5.1 Current prevalence of use, scope, duration, significance of abuse.**

Cannabis is the most widely used illicit substance in the world.<sup>187</sup> There is strong scientific support for concluding that cannabis has high potential for abuse, is actually abused and is addictive. Diagnostic guidelines by both The International Classification of Diseases (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) have designated that cannabis is addictive, and currently recognize cannabis related dependence disorders.<sup>188</sup>

**Psychological or physiological dependence:** Neuroadaptation that leads to withdrawal is based on individual responses and also depends on the extent and frequency of use. As with all addictive drugs, addiction, habituation, and abuse to cannabis is characterized by psychological symptoms during the initial abstinent phase (irritability, anger or aggression, nervousness or anxiety, sleep difficulty or insomnia, decreased appetite, weight loss, restlessness, depressed mood), but is not necessarily accompanied by physiological or physical symptoms during withdrawal. However, abstinence in heavily

addicted cannabis users unmasks physical neuroadaptation, manifested by physical, significant discomfort which can include stomach pain, shakiness/tremors, sweating, fever chills, headache. The more pronounced the withdrawal, the more predictive the symptoms are of relapse.<sup>189, 190</sup> The validity of cannabis withdrawal has been demonstrated in preclinical, clinical, and epidemiological studies. Cannabis withdrawal is reported by up to one-third of regular users in the general population and by 50-95% of heavy users in treatment or research studies.<sup>191</sup> The clinical significance of cannabis withdrawal is demonstrated by use of cannabis or other substances to relieve it, its association with difficulty quitting, sleeping, physical symptoms, increased violence among individual predisposed to violence, and worse treatment outcomes associated with greater withdrawal severity.<sup>192, 193, 194, 195, 196</sup>

**Globally:** Approximately 13.1 million people are cannabis dependent globally.<sup>197</sup> Global statistics are accumulated by the United Nations Office on Drugs and Crime (UNODC),<sup>198</sup> which provide an insight into the trends of cannabis world-wide. Cannabis is the main drug causing treatment demand in Africa and in the United States.<sup>199</sup> Comparisons between countries are challenging because the reporting of cannabis use is not uniform among countries and is not conducted annually in each country. These comparative trends may be current or out-of date or age groups may differ by country. Examples of prevalence data from some countries are given below.

In Europe, rates of use, and prevalence of CUD vary by country, as documented by the European Monitoring Center for Drugs and Drug Addiction (EMCDDA) for EU Member States.<sup>200</sup> It is estimated that cannabis has been used at least once (lifetime prevalence) by about 77 million Europeans that includes one in four of all individuals 15-64 years old. Considerable differences exist between European countries, with national prevalence figures varying from 1.6-32.5%. Among young adults (15-34 years), lifetime prevalence of cannabis use varies from 1-45.1 %, with a weighted European average of 32.2%. It is estimated that about 15.4 million (11.7%) young Europeans have used cannabis during the last year and 6.5% during the last month. In the 2011 surveys of the twenty-four Member States and Norway, lifetime cannabis use among 15-16 years ranged from 5% in Norway to 42% in the Czech Republic. A significant minority of cannabis users consume cannabis intensively. Daily or almost daily cannabis use is defined as use on 20 or more days in the month preceding survey. Data from 22 countries, suggest that around 1% of adults aged 15-64 years (~three million), report using the drug this frequently. Over two-thirds of frequent users are between 15 and 34 years, and in this range, over three-quarters are male.<sup>201</sup>

Data from the United States of America indicates that the prevalence of cannabis use increases when perceived risk of use decreases; perception of risk has declined in the face of a changing legal status of the drug, with consequent rise in daily use among youth.<sup>202</sup> The percent of high school and college students who are daily users is higher now than it has been for decades.<sup>203</sup> The prevalence of cannabis use disorder is approximately 9% of users overall (a percent calculated prior to currently high THC levels), 16% of early initiators and 25-50% of daily users.<sup>204, 205</sup> The most recent study on prevalence of cannabis use disorder among users in the US reported 30.5% of past year users harboring a CUD.<sup>206</sup> This is greater than previous estimates and may reflect the consequences of high cannabis potency and more frequent daily use. Admissions for CUD have climbed significantly recently,<sup>207</sup> as have emergency department mentions. More youth are in treatment for the disorder than for an alcohol use disorder, and college age students manifest severe problems with cannabis use or CUD.<sup>208, 209, 210</sup>

Canadians are among the highest past-year users of cannabis. Based on data from the 2012 Canadian Community Health Survey-Mental Health, 42.5% of the population reported having ever used cannabis, and 12.2% reported use in the past year, with highest rates among 18- to 24-year-olds (33.3%). Use rates differed across the country, with past-year use higher in British Columbia and Nova Scotia and lower in Saskatchewan, compared with the rest of Canada. The percentage of males who had ever used cannabis rose from 47% to 49.4% whereas the prevalence of lifetime use among females was stable at 36%.<sup>211</sup> In

contrast with the United States, cannabis use may be down among teens and young adults a new report from Statistics Canada suggests.<sup>212</sup>

Among illicit use of drugs, cannabis had the highest rate of use, with the cohort of 20-29 year olds consuming the most. In 2013, it was estimated that about 6.6 million (or 35%) people aged 14 or older had used cannabis in their lifetime and about 1.9 million (or 10.2%) had used cannabis in the previous 12 months. About one in 20 Australians (5.3%) had used in the month prior to the survey and 3.5% had used in the previous week. Among people aged 14-24, the age at which they first tried cannabis increased between 2010 and 2013, cannabis users were more likely to try cannabis in their teens, and age of first use was younger compared to other illicit drugs. One-third (32%) of recent cannabis users used it as often as weekly, and older people (50 or older) were more likely than younger people to use cannabis regularly, with at least four in 10 recent users in these age groups using it as often as once a week or more. One-fifth (19.8%) of recent cannabis users stated that all or most of their friends currently used cannabis, in contrast to only 0.8% of those who had never used the drug. In parallel with the US, between 2010 and 2013 the proportion of people aged 50-59 and 60 or older using cannabis rose (from 5.5% to 7.3% and from 0.5% to 1.2%, respectively) and is at the highest levels seen over the past decade among these age groups, which may reflect an ageing cohort of cannabis users.<sup>213</sup>

## **Section 6. The use of cannabis for medical purposes**

This section excludes individual therapeutic cannabinoids, extracts of cannabinoids approved by government agencies qualified to evaluate medicinal products, candidate cannabinoid therapeutics undergoing appraisal by an evidence-based drug approval process, individual cannabinoids of therapeutic potential assessed in preclinical research (i.e., *in vitro* or *in vivo* animal studies) or in pilot clinical studies, endocannabinoids and modulators of endocannabinoid synthesis, metabolism or trafficking. The rationale for exclusions is provided in the **Terminology** section. Essentially, it is based on a need to separate current evidence for the use of whole plant cannabis as a medicine from all other forms of evidence. CBD is also an excellent example that justifies drawing a distinction between cannabis and specific cannabinoids. Other exclusions are preclinical data, which may show promise in whole animal or tissue cultures, but cannot be presumed to translate to humans.

**6.1 Overview of safety, efficacy standards:** Several countries (including Canada, Netherlands, Israel) and 23 of 50 states in the United States have permitted the use of cannabis for medicinal purposes, with or without undergoing a systematic medicines approval process. In this update on the current status of cannabis as a medicine, a simple question is addressed: “are clinical trials that report cannabis-induced therapeutic benefit sufficient to establish currently accepted medical use?” Globally, the efficacy, safety and quality of the medical products on the market in countries have benefited enormously from a robust scientific and evidence based process. This should continue to be the central organizing principle in evaluating and approving substances for use as medicine.

By following a rigorous process, the scientific, medical, and public community can be confident that decisions are made on the basis of scientific data and judgment. This is the hallmark of an effective system for protecting the public. If cannabis is subjected to the same criteria as all medications, the medicines approval process would require that clinical trials be designed and conducted in a way that provides regulatory agencies with the necessary scientific data upon which they can make approval decisions. Without official approval, there would be no requirements for post-marketing surveillance and reporting of adverse events. Accordingly, the adverse consequences of cannabis, as outlined in Section 5 above, are based largely on cannabis used for recreational purposes, even though concerns of cannabis’ adverse effects when used for medical purposes are rising.<sup>214,215,216</sup> Also, contrary to modern medications, cannabis is a complex mixture of hundreds of chemicals of unknown concentrations, pharmacological



effects, and side-effects, delivered mainly by a currently unprecedented and controversial route of administration for medicines, smoking or vaporization (see discussion at section 6.2.3 below).

## 6.2 Cannabis: overview of dosing, entourage and administration

**6.2.1 Cannabis chemistry and dose.** Cannabis is a complex substance containing multiple cannabinoids and other compounds, and their typically wide range of THC or CBD concentrations challenge assessment of therapeutic efficacy. In order to objectively evaluate the effects of cannabis, it needs to be provided by a source with reproducible methods of production delivering controlled levels of cannabinoids. Only by systematic evaluation of known doses of pure or purified compounds or extracts, and possibly by designing more effective variants, can the field advance without compromising the rigors of the modern drug approval processes. Yet a safe therapeutic window for cannabis has not been established, and clinical trials (see below) have studied cannabis across a number of THC concentrations (1-23%). The ratio of THC to CBD has been rising in the cannabis plant.<sup>217</sup> In controlled clinical trials with cannabis, THC or CBD levels are usually the only composition of matter reported. These two cannabinoids produce distinct, and in some cases, opposite effects, a relationship that underscores the need to isolate individual cannabinoids and investigate them separately.<sup>218</sup>

Because cannabis is a botanical product, there are other substantial obstacles to meeting the statutory standard for approval. In the context of cannabis, the most active psychoactive constituent, THC, is known, but it is unclear how to evaluate the effects of the other 750 chemicals in the plant including the 104 cannabinoids of which the majority have unknown effects, interactions, and side effects.<sup>219, 220</sup> Cannabis smoke contains significant amounts of toxic chemicals, including ammonia, hydrogen cyanide and nitric oxide.<sup>221</sup> The doses of active ingredients are unknown to patients and physicians, and for some preparations, there is no assurance of product purity or absence of microbes or pesticides that can produce disease.<sup>222, 223</sup>

**6.2.2. Entourage effect:** A widely held and user-reported belief is that the benefit of smoking the whole plant product provides more relief than orally-administering the isolated cannabinoids, a belief referred to as the “entourage effect”.<sup>224</sup> This is not a trivial issue, as it is a motivating force for whole cannabis plant to be used for medical purposes in lieu of isolated compounds. Conceivably, at least three explanations may contribute to these self-reports:

(1) CBD may ease THC-induced anxiety or psychosis and their combination results in a more satisfying net effect.

(2) Pharmacokinetics may account for some of these perceived differences. Smoking produces immediate effects much faster than oral consumption, and dose can be precisely and rapidly titrated (but likely the euphorogenic effects are concurrently maximized). On the other hand, oral consumption typically results in a longer duration of effect than does smoking, conferring a possible advantage to peroral isolated cannabinoid administration. For example, a clinical trial comparing the effects of smoked cannabis with dronabinol (THC alone) suggested that, under controlled conditions, cannabis and dronabinol decreased pain, but dronabinol produced longer-lasting decreases in pain sensitivity and lower ratings of abuse-related subjective effects than cannabis.<sup>225</sup> In another pilot study, caloric intake and body weight were measured in HIV-positive cannabis smokers, and compared with placebo or dronabinol. Cannabis and dronabinol effects were comparable, with both dronabinol and cannabis well-tolerated and producing substantial and comparable increases in food intake.<sup>226</sup> All cannabinoid conditions produced significant intoxication, except for low-dose dronabinol. No other clinical trials have compared smoked cannabis to oral/spray THC or THC/CBD for other medical conditions, and few clinical trials compare cannabis with alternative existing medications, leaving the issue of whether smoked cannabis confers an advantage in efficacy and safety unresolved.

(3) Cannabinoids are not the only products of the cannabis plant with putative medicinal properties. Cannabis terpenoids share a precursor to cannabinoids (e.g. limonene, myrcene,  $\alpha$ -pinene, linalool), some of which are under investigation as candidate therapies or as facilitators of cannabinoid efficacy. Evidence is needed to prove the validity of the widely held belief and self-reporting, that whole plant cannabis is superior to isolated compounds because of synergism between various components.

**6.2.3. Smoking and vaporization:** It is generally recognized that smoking can be harmful to health.<sup>227</sup> Standard medicines are not delivered as inhaled smoke, but enter the body by other forms and routes of administration (pill, injection, topical creams, patches, inhalants, eye drops, liquid drinks, suppositories). Clinical trials measure pharmacokinetic, pharmacodynamic properties of each drug, along with metabolic rates and metabolites. To confound clinical results with cannabis, the percent of THC that enters the body is variable depending on the type of smoking ritual.<sup>228,229,230</sup> Smoking remains a controversial route of delivery, even with a recent report that found no major changes in spirometric measures of lung health of light, but not heavy, recreational cannabis smokers.<sup>231</sup> Nearly all cross-sectional and longitudinal studies evaluating cannabis use association with chronic respiratory symptoms (cough, phlegm, wheezing and breathlessness) have found a positive relationship of active smoking with symptoms of chronic bronchitis (mainly cough and phlegm) although not with shortness of breath or lung cancer. However, possible cancer risks remain for heavy smokers.<sup>232,233</sup> Whether vaporizing cannabis is a safer alternative to smoking remains uncertain, as health benefits derived from reducing toxic smoke components, (except in persons with chronic lung disease), need to be weighed against hazards of acute intoxication and long term consequences to the brain. Two studies with vaporized cannabis showed modest relief of neuropathic pain,<sup>234,235</sup> with one at a very low dose of THC (1.29%). In support of this method of delivery, vaporized or smoked cannabis yielded similar maximal blood levels indicating similar delivery efficiency, but a wide range of inter-subject blood levels of THC.<sup>236</sup> Given similar blood levels from both routes of administration, is it not surprising that CB1 receptor activation was comparable with smoked or vaporized sources of THC.<sup>237</sup>

### 6.3 Safety

**6.3.1. Missing safety data:** Isolated cannabinoids have undergone a number of RCTs documenting safety, efficacy and side effect profiles as required in a formalized drug approval process, whereas few RCTs are reported for whole plant cannabis. In the absence of long term clinical trials, most data by necessity is extrapolated from recreational users. In the literature, it was not possible to identify trials of long duration that investigate outcomes in people using cannabis long-term for medical conditions, even though cannabis is used primarily by people with chronic medical conditions (e.g. AIDS neuropathy, AIDS wasting, multiple sclerosis, chronic pain, seizures, others). Current estimates are that 25-50% of daily cannabis users develop an addiction to cannabis.<sup>238</sup> On the basis of current information and especially in view of negative side effects of chronic use (addiction, compromised cognition and executive control), one cannot be assured that cannabis can be safely used under medical supervision for long term open-ended use.

Key information about side-effects and safety would be collected if cannabis went through the normal evaluation process for approval as a medicine. Of RCTs, the majority of trials do not report a full dose-response evaluation, inclusion criteria generally require subjects to be experienced cannabis users, trials are of short duration (days to weeks, not 6-12 months), the sample populations are low, they do not assess quality of daily life or function when using a psychoactive substance (e.g. driving, work quality, school attentiveness, cognitive impairment) or effects after prolonged use (e.g. addiction, cognition, executive function, motivation, psychosis).

**6.3.2. Medical conditions with cognitive decline:** Side effects of cannabis have to be viewed in the

context of immediate effects and after repeated long term use. In research of subjects under the influence of cannabis, dose-related impairments of immediate and delayed recall of information can be quantified. Various phases of learning and memory can be affected, as well as signs of depersonalization, distorted sensory perception, and altered time perception. Executive function in cannabis users (attention, concentration, decision-making, impulsivity, self-control, reaction time, risk taking, verbal fluency and working memory) is impaired acutely in a dose-dependent manner.<sup>239</sup> Regular cannabis use for medicinal purposes is a relatively recent regimen that its long-term effects on seriously ill people is comparatively unknown, especially among those harboring disease-related cognitive decline (e.g. cancer, HIV/AIDS, multiple sclerosis, Alzheimer's, Parkinson's disease, certain seizure disorders). An illustration of this is in cancer, where chemotherapy promotes cognitive decline before, during or after, with memory loss, loss of concentration and attention the most frequent symptoms.<sup>240, 241</sup> Conceivably, the combination of chemotherapy and cannabis reduces cognitive functions in additive or synergistic ways. Yet the impact of cannabis on parameters of cognition has not been tested, although the number of patients using cannabis during chemotherapy is growing. For multiple sclerosis, another disease beleaguered by cognitive impairment, it is now recognized that cannabis worsens cognitive deficits.<sup>242</sup> Reports on cannabis-induced relief of physical symptoms in other neurodegenerative disorders with cognitive impairment (Parkinson's disease, Alzheimer's disease), do not judiciously measure cognition. Cannabis may compromise quality-of-life for these populations but this parameter remains inadequately explored.

**6.3.3 Long term effects:** A significant number of individuals report paranoia, persecutory ideas, or hallucinations while under the influence of cannabis<sup>243</sup> and with drug-naïve study subjects, high drop-out rates would compromise the integrity of the clinical trial. For chronic users, other side effects can include altered brain structure and brain circuits impaired short-term memory, compromised judgment and decision-making, and mood effects that can range from severe anxiety manifest as paranoia or even psychosis, especially after high-doses, as reviewed earlier. Cannabis can reduce motor coordination alone, or combined with alcohol, slow the reaction time of drivers.<sup>244</sup> Cannabis smoking can cause or worsen breathing problems such as bronchitis or chronic cough and evidence is increasing that it may cause serious cardiovascular problems in some users.<sup>245</sup> The impact of long-term use on young people, whose frequent use for asserted medical reasons is increasing rapidly, cannot be adequately predicted at this time either.

There are no recent clinical trials in a sufficiently large cohort of cannabis-naïve subjects with a specific medical condition to conclude that there is an acceptable level of safety for use of cannabis under medical supervision.

## 6.4 Evidence of Cannabis for Medicinal Use

**6.4.1 Use of cannabis for specific purposes, internationally:** A recent, international survey of 31 countries investigated self-reported medicinal use of cannabis (and cannabinoids). Respondents (953) from the United States, Germany, Canada, France, the Netherlands, and Spain were generally male (64%), relatively young (mean age 40.7 years) with a smaller cohort using over the age of 51 (24%), and far fewer past the age of 60 or 70 (6%, 1%). Cannabis was used primarily for back pain (11.9%), sleeping disorders (6.9%), depression (6.7%), injury or accident-generated pain (6.2%), and multiple sclerosis (4.1%).<sup>246</sup> With the exception of multiple sclerosis, and neuropathic pain, randomized controlled trials with cannabis use for these symptoms are scant.

It is within reason to acknowledge that certain people report relief and symptom improvement while under the influence of cannabis, as corroborated by surveys, case-based studies, anecdotal self-reports, laboratory-based short-term trials. Evidence from RCTs is presented below, with sources from primary manuscripts and 10 meta-analyses.<sup>247,248</sup>

It should be noted that the psychoactive responses engendered by cannabis confound clinical research, as it is a significant obstacle to designing randomized, double-blinded clinical trials. Nor are there adequate, well-controlled double-blinded long-term RCTs demonstrating efficacy in drug-naïve populations compared with cannabis-using populations.<sup>249</sup> The majority of RCT trials recruit experienced cannabis using subjects for a number of reasons, including concerns of unacceptably high drop-out rates among cannabis-naïve subjects.<sup>250</sup>

#### **6.4.2 Neurological diseases or symptoms**

Several recent reviews and meta-analyses have weighed in on the therapeutic indications for neurological diseases.<sup>251, 252, 253, 254</sup> Many degenerative neurological diseases and certain pain conditions are characterized by cognitive impairment or decline, in addition to physical signs of impairment. A characteristic consequence of smoked cannabis is to compromise cognition. This effect needs to be considered in weighing the risks-benefits of cannabis.

##### **6.4.2.1 Multiple Sclerosis**

Multiple sclerosis (MS) is an inflammatory, autoimmune, degenerative disease of the central nervous system.<sup>255</sup> It is among the most common causes of non-traumatic neurological disability in young adults of northern European descent.<sup>256, 257</sup> Globally it affects about 2-3 million people,<sup>258</sup> with incidence particularly high in Northern Europe and other countries settled by Northern Europeans. The consequence of neuronal loss is the development of pain, spasticity, incontinence, cognitive decline, limb tremors, fatigue, sleep disturbances and all of which impact quality of life.<sup>259, 260</sup> One study from the United Kingdom reported that approximately 14-18% of MS patients used cannabis for symptom relief from pain, spasticity and insomnia.<sup>261</sup> Given that cognitive impairment occurs in approximately 40-60% of patients with multiple sclerosis, is associated with structural and functional brain changes,<sup>262, 263</sup> and given the effects of MS on cognition, patients who smoke cannabis may be particularly vulnerable to cognitive deficits and brain changes attributed to cannabis. MS patients who smoke cannabis display additional deterioration in measures of cognition, including processing speed, memory, executive functioning, and deficits in recruiting brain regions during a memory task.<sup>264, 265, 266</sup> Furthermore, cannabis use by MS patients resulted in more wide spread cognitive deficits. The deficits correlated with loss of tissue volume in subcortical, medial temporal and prefrontal regions. Reductions in brain volume were associated with more extensive cognitive impairment in the cannabis-using MS population compared to the non-cannabis MS group. This association between cannabis use, cognitive impairment and structural brain changes in MS patients<sup>267</sup> is a cautionary example of the multiple factors to consider along with the therapeutic potential of cannabis.

There is some evidence that the endocannabinoid system is dysregulated in MS.<sup>268</sup> In an animal model of MS, the neurodegeneration rate can be reduced by administration of CB2 agonists, exogenous 2-arachidonoylglycerol (2-AG) administration, or elimination of the major degrading enzyme FAAH, in transgenic mice.<sup>269, 270, 271</sup> 2-AG is a full agonist at the human CB2 receptor, whereas anandamide is a weak partial agonist and local concentrations may even temper 2-AG actions.<sup>272</sup> To date there are no reports of clinical trials testing the efficacy of modulating endocannabinoid levels neither for symptom relief nor neuroprotection. Cannabinoid agonists (THC, Sativex®) alleviate the symptoms,<sup>273, 274</sup> but evidence that cannabinoids can function as neuroprotective agents is weak, as THC failed to attenuate MS progression or disability.<sup>275</sup> MS is characterized by a wide range of cognitive and physical symptoms; clinical trials with cannabis need to consider whether cannabis improves or compromises a range of symptoms, including cognition, simultaneously and whether the costs outweigh the benefits of treatment.<sup>276</sup>

*Randomized controlled trials with cannabis:* Three RCTs were identified which used inhaled or vaporized cannabis to treat MS symptoms.

1. A double-blind randomized placebo-controlled study of inhaled cannabis smoke on postural responses was performed in 10 adult patients (five female, five male) with spastic MS and 10 normal volunteers matched for age, sex, and weight. A computer-controlled dynamic posturographic platform measured platform movements. Smoking one cannabis cigarette (1.54% THC) increased postural tracking error in both the patients and normal control subjects, with eyes open or shut. Tracking errors were higher for patients than controls and response speed of the patients was lower, with eyes closed. The conclusion of the study investigators was that cannabis smoking worsens posture and balance in MS patients.<sup>277</sup>

2. Spasticity is a common and poorly controlled symptom of multiple sclerosis. In this placebo-controlled, crossover trial, adult patients with multiple sclerosis and spasticity were randomly assigned to either smoked cannabis (4% THC), once daily for three days, or to identical control placebo cigarettes, once daily for three days.<sup>278</sup> After a washout interval of 11 days, participants crossed over to the opposite group. The primary outcome was change in spasticity measured by patient score on a modified Ashworth scale. Secondary outcomes included: (a) patients' perception of pain (visual analogue scale), (b) a timed walk, (c) cognition, and (d) ratings of fatigue. Of 37 participants, 80% were experienced cannabis users, and 30 completed the trial. Seven subjects dropped out of the study, the majority cannabis-naïve. Treatment with smoked cannabis resulted in a reduction in Ashworth scale ratings of spasticity, patient self-reports of spasticity, of pain, and a significant reduction in cognitive function. Walk times did not change. Dizziness (23%), headaches (20%), fatigue (20%) nausea (11%), too "high" (6%) were reported side effects. Authors concluded that smoked cannabis was superior to placebo in spasticity and pain reduction in participants.

3. Another RCT may reside on the "margins" of this review, because oral THC was compared with an oral "cannabis sativa extract", but no information is provided on whether the extract is analogous to nabiximols (excluded from this survey), or is a crude extract of whole plant cannabis containing its constituents.<sup>279</sup> This randomized, double-blind, placebo-controlled, twofold crossover study was conducted in 16 patients with MS for four weeks. Both drugs were safe, but adverse events were more common with plant-extract treatment, compared with THC. Compared with placebo, THC or plant-extract did not reduce spasticity. Both THC and plant-extract treatment worsened the participant's global impression.

#### 6.4.2.2 Neuropathic pain

Pain can be classified as acute or chronic, or by site of origin (nociceptive) or nerves (neuropathic). Neuropathic pain occurs in various disease states (e.g. diabetes, HIV/AIDS, post-traumatic pain, cancer, excess alcohol use, rheumatoid arthritis) and can be a persistent, debilitating condition. HIV neuropathic pain affects 30% or more of HIV-infected individuals and some antiretroviral therapies can worsen the condition. Current analgesics and other medications offer incomplete pain relief. HIV-infected individuals report improvements in health from smoking cannabis. Of over 200 people with HIV/AIDS, 23% used cannabis in the previous month.<sup>280,281</sup> The association between cannabis use for psychoactive purposes and cannabis used medically for HIV/AIDS is relevant,<sup>282</sup> with considerations including cognitive impairment, as both cannabis use and duration of HIV infection may affect cognitive functioning that may impair their ability to follow important treatment guidance.<sup>283,284</sup> While evidence for an effect of inhaled cannabis on chronic neuropathic pain is promising, trials followed their patients for a maximum of two weeks. Long-term trials, which also examine pragmatic outcomes, are needed to increase confidence that short term trials, conducted largely in experienced cannabis users, are relevant to an overall cost-benefit analysis of long term cannabis use to treat chronic neuropathic pain.

#### *Randomized controlled trials with cannabis:*

Six recent manuscripts were identified reporting randomized controlled clinical trials with smoked or vaporized cannabis. Five were recently summarized positively in a review co-authored by investigators of the primary studies.<sup>285</sup> The pilot studies showed beneficial effects on alleviating pain, and by inhalation,

enabled patients to titrate the effects. Yet these six reports did not establish a conclusive dose effect vs adverse events therapeutic window, as doses used varied. Acceptable limits of cognitive impairment were not described and no report addressed cognitive impairment outside a clinical research setting. Others have reviewed the overall evidence for cannabis and cannabinoids for pain.<sup>286,287</sup> No RCTs are reported for ingested cannabis, which displays variable onset times, inability to titrate doses, and more side effects.<sup>288</sup> Edibles containing cannabis, because of pharmacokinetic differences, may be more likely to induce psychosis, which may outlast the period of intoxication.<sup>289,290</sup> The peak serum concentration of orally absorbed THC is delayed compared with inhaled administration and is not reached until one to three hours have elapsed. If more than the suggested serving size is consumed (e.g. > THC 100 mg) because users felt no effect and did not wait three hours for THC to be absorbed, they may undergo acute toxicity. Differences in oral metabolism are likely play a role in the development of acute psychosis in these patients who regularly smoke cannabis. Oral administration produces the active metabolite (11-OH-THC), which is proposed by Favrat et al to reach the target (CB1 receptor) more efficiently.<sup>291</sup>

### 1. Diabetic neuropathy (1%, 4%, 7% THC):

A randomized, double-blinded, placebo controlled crossover study in 16 patients with painful diabetic peripheral neuropathy assessed the short-term efficacy and tolerability of inhaled cannabis.<sup>292</sup> There was a modest reduction in spontaneous pain for the low and moderate dose but a marginal effect at the highest dose (% reduction in pain: placebo 61.2%; 1% THC: 66.7%; 4% THC: 70.3% and 7% THC: 65.5%) The high dose impaired cognition, and the moderate and high doses elicited euphoria or somnolence. The time to minimum pain was not dose-dependent. The report is inconsistent with another study showing pain improvement only at 9.4% THC.<sup>293</sup>

### 2. HIV-associated sensory neuropathy (3.5% THC):

This study measured the effect of smoked cannabis on neuropathic pain of HIV-associated sensory neuropathy and an experimental pain model.<sup>294</sup> Primary outcome measures included ratings of chronic pain and the percentage achieving 30% reduction in pain intensity. Greater than 30% reduction in pain was reported by 52% in the cannabis group and by 24% in the placebo group, with findings comparable to oral drugs used for chronic neuropathic pain. Adverse events were of far higher prevalence in the cannabis than the placebo group and included anxiety, sedation, confusions, dizziness, disorientation, paranoia and nausea, with most achieving robust statistical significance. It is not possible to exclude relaxation and euphoria from the pain relief.

### 3. Neuropathy: low to moderate doses (1.29%, 3.53% THC):

Wilsey et al<sup>295</sup> conducted a similar study with smoked cannabis and then followed up in a larger cohort, assessing vaporized cannabis in a broader range of neuropathies with two doses of THC (1.29% and 3.53%) compared with placebo.<sup>296</sup> Both active study medications provided statistically significant 30% reductions in pain intensity, comparable to two commonly used anticonvulsants used for neuropathic pain treatment. Psychomotor tasks revealed significant cannabis impairment at 60 minutes and at four hours, with performance worse at the higher THC dose. The author concluded that cannabis effects “on learning and memory, where effect sizes were in the small to medium range, were unlikely to have significant impact on daily functioning”. Although earlier work suggested that frequent cannabis users become tolerant to cannabis-related performance-impairing effects, more recent comparisons of cannabis-related effects on cognitive performance of frequent users suggest impairment on a variety of cognitive tasks, which may be dose and age-dependent.<sup>297</sup>

### 4. HIV/AIDS neuropathy (1-8% THC):

Ellis et al<sup>298</sup> also assessed smoked cannabis for HIV/AIDS neuropathy in a cross-over design. Among 28 completers (27 experienced cannabis users), pain relief was greater with cannabis than placebo, with 46% achieving at least 30% pain relief with cannabis versus placebo (18%). Most side effects were mild and self-limited, but two subjects experienced treatment-limiting toxicities. Smoked cannabis was generally

well tolerated and effective when added to concomitant analgesic therapy with medically refractory pain. Analgesia duration was not assessed in this short-term study. Concentration difficulties, fatigue, sleepiness or sedation, increased duration of sleep, reduced salivation, and thirst were reported side effects.

#### 5. Neuropathy (2.5-9.4% THC):

Ware et al<sup>299</sup> tested three doses of smoked cannabis for chronic neuropathic pain (2.5%, 6%, 9.4% THC) in which 18/24 were experienced cannabis users. Euphoria or “high” was reported on three occasions throughout the trial, but there was no evidence of euphoria during the three hours following the first dose of each cycle regardless of THC potency. Finally, a study explored the pharmacokinetics, safety, tolerability, efficacy, and ease of use of a portable thermal-metered-dose inhaler for cannabis in a cohort of eight patients with chronic neuropathic pain on a stable analgesic regimen including cannabis.<sup>300</sup> A significant 45% reduction in pain intensity was noted at 20 minutes post inhalation, returning to baseline within 90 minutes. Tolerable, lightheadedness, lasting 15-30 minutes was the only reported adverse event.

#### 6.4.2.3 Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common type of dementia, and is characterized by a number of debilitating symptoms, including cognitive decline, sleep disorders, and behavioral changes.<sup>301</sup> There is some interest in assessing the therapeutic potential of cannabinoids in AD, especially for sedative effects or sleep disorders. Assessment of memory and cognitive function as outcome measures with long term use of cannabinoids is critical, as this class of drugs affects memory, cognitive functions, and balance in frail older people. There are no RCTs with whole plant cannabis to treat symptoms of Alzheimer’s disease or progression of the disease.<sup>302</sup> Some intriguing positive benefits relevant to the degenerative process are derived from cellular or imperfect animal models.<sup>303</sup> Four RCTs are reported with isolated cannabinoids, but little is known about safety in this population, especially as long term exposure to cannabinoids increases the risk of psychiatric disorders and dysfunction (e.g., cognitive abnormalities, psychotic, mood disorders).

#### 6.4.2.4 Other Neurological Conditions

- Epilepsy: There are no reported RCT with cannabis use in any form of epilepsy.<sup>304</sup>
- Huntington Disease Dyskinesias: There are no RCT with cannabis for this condition.
- Parkinson’s Disease (Levodopa-Induced Dyskinesias): There are no RCT with cannabis for this condition.<sup>305</sup> A recent an open label trial reportedly found positive improvements in Parkinson’s disease patients that smoked cannabis.<sup>306</sup> Others recommend more research with isolated cannabinoids.<sup>307</sup>
- Cervical Dystonia: There are no RCT with cannabis for this condition.
- Tics of Tourette Syndrome: There are no RCT with cannabis for this condition.

#### 6.4.3. AIDS Wasting, Cachexia and Appetite Enhancement

Studies have shown that smoked or ingested cannabis, either as a botanical or a synthetic THC (dronabinol), improves appetite, increases weight, and improves quality of life in HIV/AIDS patients. Seven RCTs with smoked cannabis or individual cannabinoids of short duration (21-84 days) were identified for the treatment of AIDS in a small number of patients.<sup>308</sup> Other measured changes included viral load, weight, body fat, appetite, caloric intake nausea and vomiting, performance and mood.

#### 6.4.3.1 AIDS viral load

Cannabis (3.95%), dronabinol or placebo had no adverse effect on viral load or protease inhibitor pharmacokinetics.<sup>309</sup> Smoked and oral cannabinoids appeared safe in people with HIV infection in the short duration of the study (21 days).

#### 6.4.3.2 AIDS and appetite

Appetite enhancement is indicated in diseases characterized by loss of appetite and wasting. Tolerability and efficacy of smoked cannabis (1.8%; 2.8%; 3.9% THC) and oral dronabinol in HIV-positive cannabis smokers was compared in those with and without a clinically significant loss of muscle mass, component of AIDS wasting. Cannabis and the lower dronabinol doses (10, 20 mg) were well tolerated (e.g. few physical symptoms e.g. nausea, dizziness, intoxication, headache, significant increases in ratings of “good drug effect”) in both groups of participants. Cannabis and dronabinol significantly increased caloric intake in the low bioelectrical impedance analysis (BIA) group but not in the normal BIA group. (BIA estimates total body water, a measure of fat-free body mass). Drug effects on cognitive performance were designated as minor. The study was compromised as subjects were allowed to use cannabis at home throughout the study (no regulated doses), with cannabis prohibited on the morning of testing. For experienced cannabis smokers with clinically significant muscle mass loss, both dronabinol and cannabis produce substantial and comparable increases in food intake without producing adverse effects.<sup>310</sup> These findings question the need for a smoked product if there is an approved medicinal product which is equally effective.

#### 6.4.3.3 HIV/AIDS and appetite, mood, cognitive performance, physiologic measures, sleep

A placebo-controlled within-subject design evaluated cannabis and dronabinol across a range of behaviors: HIV-positive cannabis smokers (n=10) completed two, 16-day inpatient phases.<sup>311</sup> Each dronabinol (5 and 10 mg) and cannabis (2.0%, 3.9% THC) dose was administered four times daily for four days. Compared with placebo, cannabis and dronabinol dose dependently increased daily caloric intake and body weight in HIV-positive cannabis smokers. All cannabinoid conditions produced significant intoxication, except for low-dose dronabinol (5 mg), with intoxication rated as “good drug effect”. There was no impairment of cognitive performance. Effects of cannabis and dronabinol were comparable, except that only cannabis (3.9% THC) improved ratings of sleep. These data suggest that for HIV-positive cannabis smokers, both dronabinol (at doses eight times current recommendations, likely because of tolerance due to prior heavy cannabis use), and cannabis produced substantial and comparable increases in food intake. A sustained effect of cannabis on AIDS-related morbidity, mortality, safety in patients on effective antiretroviral therapy has not been shown. The available evidence is insufficient or low quality<sup>312</sup> to alter medical and regulatory guidance.

**6.4.4. *Cancer and symptom management:*** Cannabis has been proposed to alleviate symptoms of cancer, including reduced appetite, chemotherapy-induced nausea and vomiting, pain and even to attenuate the disease process.

**6.4.4.1 *Cancer, chemotherapy and anti-emesis.*** Chemotherapy-induced nausea and vomiting were inadequately controlled in the 1960s and 1970s, motivating investigation of the anti-emetic properties of cannabinoids and leading to the approval of nabilone and synthetic THC (dronabinol). There have been only three small clinical trials on the use of cannabis in cancer patients.<sup>313</sup> All three studies assessed antiemetic activity, with different patient populations and chemotherapy regimens. One study demonstrated no effect, the second study showed a positive effect versus placebo. The report of the third study did not provide enough information to characterize the overall outcome as positive or neutral. There are no published data on the use of cannabis for other cancer-related or cancer treatment-related symptoms.<sup>314</sup>

Some patients prefer smoked cannabis over oral cannabinoids, with rationales that include ability to self-titrate smoked cannabis, the swallowing of pills is difficult while experiencing emesis, onset of relief is faster with smoking, and the whole plant (“entourage”) is more effective.<sup>315</sup> Side-by-side clinical trials with oral cannabinoid compared with smoked cannabis in HIV/AIDS (see above) show scant evidence for



therapeutic advantage of smoked cannabis. Furthermore, if the goal is to prevent nausea, factors such as speed of brain entry, challenges of swallowing pills while vomiting, dose titration, are not important factors; an oral cannabinoid can be administered long before chemotherapy to avoid its unpleasant side effects. Inhaled cannabis engenders a higher rate of brain entry and associated undesirable side effects, which can include intoxication, anxiety, acute psychotic reactions, and orthostatic hypotension.<sup>316</sup> Recent drug discovery programs have introduced newer anti-nausea drugs that are superior to cannabinoids in clinical trials. It is also possible that non-psychoactive isolated cannabinoids may prove to be effective for nausea and vomiting.<sup>317</sup> A significant proportion of older cancer patients with no previous cannabis experience refused to continue its use because they found the psychoactive effects too unpleasant. For such reasons, there is doubt whether smoked cannabis will find widespread clinical application, except among those who have previously used it for nonmedical purposes.<sup>318</sup> Paradoxically, cannabinoids can be both anti-emetic and pro-emetic. A cannabinoid hyperemesis syndrome has recently been described in which persistent and regular cannabis use (i.e., daily or weekly use for more than one year) is associated with episodic nausea and vomiting<sup>319</sup> and nonresponse to treatment for cyclic vomiting other than hot showers.<sup>320</sup>

6.4.4.2 Cannabis, symptoms and anti-tumor activity: At present, data show contradictory results.<sup>321 322</sup> The promise of cannabinoids as anti-tumor agent stems from preclinical research, using either cultured cells derived from human or rodent tumors, or mouse tumor models. These initial studies are insufficient to satisfy stringent criteria for recommending cannabis to test human cancers. Cell cultures have yielded contradictory results, with THC potentiating or inhibiting tumor proliferation, as a function of tumor type and its pathology. In one small Phase I trial of nine patients with aggressive glioblastoma multiforme treated with direct infusions of THC,<sup>323</sup> THC did not extend the life span of these patients.

#### **6.4.5. Crohn's Disease**

There is evidence that cannabis use is higher in patients with inflammatory bowel diseases,<sup>324</sup> but until recently, these reports were not subjected to controlled trials. In a prospective trial to determine whether cannabis can induce remission, 21 cannabis-naïve patients with Crohn's Disease who did not respond to therapy with steroids, immunomodulators, or anti-tumor necrosis factor- $\alpha$  agents were assigned randomly to groups given cannabis cigarettes (THC, 23%; less than 5% CBD) twice daily or placebo cannabis (with THC extracted) for eight weeks of treatment and two weeks thereafter. Complete remission was achieved in five of 11 subjects in the cannabis group (45%) and one of 10 in the placebo group but this was not statistically significant. A positive clinical response was observed in 10 of 11 subjects in the cannabis group and in four of 10 in the placebo group. Three patients in the cannabis group were weaned from steroid dependency and subjects reported improved appetite and sleep, with no significant side effects. After an additional 2-week washout period, the mean self-reported scores of the cannabis group rebounded to pretreatment levels, and at 10 weeks there was no difference in mean rating scale results between the placebo and cannabis groups. The authors concluded that cannabis use produced a clinical, steroid-free benefit in patients with active Crohn's disease, but the results were not statistically significant. No independent measures (e.g. endoscopy) were performed to confirm self-reported improvements in the disease state. The primary end point of the study, induction of remission, was not achieved but this short course (8 weeks) of THC-rich cannabis produced clinical, steroid-free benefits to patients with active Crohn's disease, compared with placebo, without side effects.<sup>325</sup> Intriguingly, there was no difference between experimental and placebo groups in side effects, including sleepiness, nausea, and confusion, memory impairment concentration, despite a 23% THC concentration. Patients denied any withdrawal symptoms when stopping cannabis use at the end of the study. Whether this reflects a reduction of inflammation or only amelioration of symptoms, such as a reduction in pain and improved appetite, remains unclear. Cannabis may conceivably reduce inflammation indirectly by reducing stress, but symptomatic improvement without a reduction in inflammation could cause ongoing intestinal structural damage.

#### **6.4.6. Post-traumatic stress disorder (PTSD)**

Post-traumatic stress disorder (PTSD) is a state of mind activated by either witnessing or experiencing a shocking, frightening, horrifying episode(s). If symptoms continue or get worse after prolonged periods of time (months or years later), interfere with daily life and function, and persist long after there is no danger of a recurrence, the condition is designated as PTSD. There are no large scale RCTs with cannabis to alleviate PTSD symptoms. On the contrary, cannabis use may impede the effectiveness of treatment for PTSD, and is associated with poorer clinical outcomes with PTSD.<sup>326,327</sup>

#### **6.4.7. Glaucoma**

Glaucoma is an array of ocular disorders which leads to visual deficits or blindness.<sup>328</sup> Elevated intraocular pressure (IOP) is a primary cause of vision loss. Cannabis lowers blood pressure and may also reduce aqueous humor production via cannabinoid receptor activation, pharmacological actions that temporarily reduce IOP.<sup>329,330,331</sup> A reduction in blood pressure can be both helpful and harmful as reduced blood perfusion may compromise optic nerve function. Because of its short duration of action on blood pressure, it is necessary to smoke cannabis six to eight times each day to achieve a constant decrease in IOP, which conceivably will compromise daily function, impair cognition in the elderly, and with continuous use, initiate progression to addiction in the vulnerable<sup>332</sup>. Another challenge to using cannabis is the development of tolerance to its pharmacological actions in the eye,<sup>333</sup> which raises significant concerns about the cost-benefit for its use in treating glaucoma. An alternative approach is to focus on modulating the endocannabinoid system, which may circumvent the toxic and adverse effects of cannabis.<sup>334</sup> Cannabinoids failed to reduce IOP in glaucoma patients in a small clinical trial.<sup>335</sup>

### **Summary and Conclusions**

It has been advanced that whole plant cannabis can be used for multiple therapeutic purposes. The evidence presented on potential medical uses and risks of cannabis in humans herein is focused on unprocessed, botanical cannabis and not isolated cannabinoids, some of which are medically approved. The medical benefits of cannabis continue to be debated globally, as they have been for nearly 150 years. Cannabis extracts were listed in the British, and later in the US Pharmacopeia for sedative and anticonvulsant effects, but were removed a century later, for similar reasons that fuel the current debate. The movement to revive cannabis as a medicine to alleviate pain, seizure disorders, enhance appetite, and relieve a myriad of other neurological or metabolic diseases, is driven by multiple factors. These include inadequacies in current medications to treat specific symptoms or diseases, along with self-reported benefits derived from cannabis.

With the discovery of the endocannabinoids and their receptors in the brain and other tissues, the rationale for, and research of medicinal effects of cannabis or isolated cannabinoids has entered a modern context. In brain, endocannabinoids and their receptors play a fundamental role in regulating pleasure, memory, thinking, concentration, body movement, awareness of time, appetite, pain, sensory processing (taste, touch, smell, hearing, and sight), and brain development. In peripheral tissues, the widespread distribution of endocannabinoid signaling systems conceivably account for the myriad effects and therapeutic potential of cannabinoids. Especially for psychoactive drugs such as cannabis, rigorous criteria for its approval as a safe and effective medicine need to be fulfilled, along with a meticulous cost-benefit analysis to weigh its therapeutic potential alongside its detrimental effects to individuals and to society.

## References

- 1 Gloss D. An Overview of Products and Bias in Research. *Neurotherapeutics*. 2015; 12(4): 731-4.
- 2 Single Convention on Narcotic Drugs: As amended by the 1972 Protocol amending the Single Convention on Narcotic Drugs, 1961, Vienna, 21 February 1971, United Nations, Treaty Series, vol. 1019, p. 1 ([https://www.unodc.org/pdf/convention\\_1961\\_en.pdf](https://www.unodc.org/pdf/convention_1961_en.pdf), accessed 11 December 2015).
- 3 Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, Manly SP, Wilson L, Seale S, Cutler SJ, Ross SA. Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa. *J Nat Prod*. 2015 Jun26; 78(6): 1271-6.
- 4 Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci*. 2009; 30(10): 515-27.
- 5 Chen CY, Anthony JC. Epidemiological estimates of risk in the process of becoming dependent upon cocaine: cocaine hydrochloride powder versus crack cocaine. *Psychopharmacology (Berl)*. 2004 Feb; 172(1): 78-86.
- 6 Chabrol H, Roura C, Armitage J. Bongs or water pipes, a method of using cannabis linked to dependence. *Can J Psychiatry* 2003; 48: 709.
- 7 Baggio S, Deline S, Studer J, Mohler-Kuo M, Daepfen JB, Gmel G. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. *J Adolesc Health*. 2014 Feb; 54(2): 235-40.
- 8 Agrawal A, Lynskey MT. Tobacco and cannabis co-occurrence: does route of administration matter? *Drug Alcohol Depend*. 2009 Jan 1; 99(1-3): 240-7.
- 9 Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci*. 2009 Oct; 30(10): 515-27.
- 10 Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G, Pagano E, Di Marzo V, Izzo AA. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. *Biochem Pharmacol*. 2013 May 1; 85(9): 1306-16.
- 11 Pagano E, Montanaro V, Di Girolamo A, Pistone A, Altieri V, Zjawiony JK, Izzo AA, Capasso R. Effect of non-psychotropic plant-derived cannabinoids on bladder contractility: focus on cannabigerol. *Nat Prod Commun*. 2015 Jun; 10(6): 1009-12.
- 12 Kalant H, Medicinal use of cannabis: history and current status. (<http://www.parl.gc.ca/content/sen/committee/371/ille/presentation/kalant-e.htm>, accessed 11 December 2015).
- 13 Kalant OJ. Report of the Indian Hemp Drugs Commission, 1893-94: A critical review. *Int J Addictions* 1972; 7: 77-96.
- 14 Eddy M. Medical marijuana: Review and analysis of federal and state policies 2010; Congressional Research Service; RL33211 (<https://www.fas.org/sgp/crs/misc/RL33211.pdf>, accessed 11 December 2015).
- 15 Elsohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. *Life Sci*. 2005 Dec 22; 78(5): 539-48.
- 16 Ahmed SA, Ross SA, Slade D, Radwan MM, Zulfikar F, Matsumoto RR, Xu YT, Viard E, Speth RC, Karamyan VT, ElSohly MA. Cannabinoid ester constituents from high-potency Cannabis sativa. *J Nat Prod*. 2008 Apr; 71(4): 536-42.
- 17 Radwan MM, Elsohly MA, Slade D, Ahmed SA, Wilson L, El-Alfy AT, Khan IA, Ross SA. Non-cannabinoid constituents from a high potency Cannabis sativa variety. *Phytochemistry*. 2008 Oct; 69(14): 2627-33.
- 18 Niesink RJ, Rigter S, Koeter MW, Brunt TM. Potency trends of  $\Delta(9)$ -tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. *Addiction*. 2015 Aug 1. [Epub ahead of print]
- 19 Swift W, Wong A, Li KM, Arnold JC, McGregor IS. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. *PLoS One*. 2013 Jul 24; 8(7): e70052.
- 20 Zamengo L, Frison G, Bettin C, Sciarone R. Variability of cannabis potency in the Venice area (Italy): a survey over the period 2010-2012. *Drug Test Anal*. 2014 Jan-Feb; 6(1-2): 46-51.
- 21 Bruci Z, Papoutsis I, Athanaselis S, Nikolaou P, Pazari E, Spiliopoulou C, Vyshka G. First systematic evaluation of the potency of Cannabis sativa plants grown in Albania. *Forensic Sci Int*. 2012 Oct 10; 222(1-3): 40-6.
- 22 Stogner JM, Miller BL. Assessing the Dangers of "Dabbing": Mere Marijuana or Harmful New Trend? *Pediatrics*. 2015 Jul; 136(1): 1-3.
- 23 Tipparat P, Natakankitkul S, Chamnivikaipong P, Chutiwat S. Characteristics of cannabinoids composition of Cannabis plants grown in Northern Thailand and its forensic application. *Forensic Sci Int*. 2012 Feb 10; 215(1-3): 164-70.

- 
- 24 Baggio S, Deline S, Studer J, Mohler-Kuo M, Daeppen JB, Gmel G. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. *J Adolesc Health* 2014; 54: 235-40.
- 25 Azorlosa JL, Greenwald MK, Stitzer ML. Marijuana smoking: Effects of varying puff volume and breathhold duration. *J Pharmacol Exp Ther* 1995; 272: 560-569.
- 26 Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM. Marijuana smoking: Effect of varying delta-9-tetrahydrocannabinol content and number of puffs. *J Pharmacol Exp Ther* 1992; 261: 114-122.
- 27 Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, Desjardins S. A comparison of mainstream and sidestream marijuana and tobacco cigarette smoke produced under two machine smoking conditions. *Chem Res Toxicol*. 2008 Feb; 21(2): 494-502.
- 28 Biehl JR, Burnham EL. Cannabis Smoking in 2015: A Concern for Lung Health? *Chest*. 2015 Sep 1; 148(3): 596-606. 15-0447.
- 29 Bloor RN, Wang TS, Spanel P, Smith D. Ammonia release from heated 'street' cannabis leaf and its potential toxic effects on cannabis users. *Addiction*. 2008 Oct; 103(10): 1671-7.
- 30 Giroud C, de Cesare M, Berthet A, Varlet V, Concha-Lozano N, Favrat B. E-Cigarettes: A Review of New Trends in Cannabis Use. *Int J Environ Res Public Health*. 2015 Aug 21; 12(8): 9988-10008.
- 31 Morean ME, Kong G, Camenga DR, Cavallo DA, Krishnan-Sarin S. High School Students' Use of Electronic Cigarettes to Vaporize Cannabis. *Pediatrics*. 2015 Sep 7. pii: peds.2015-1727.
- 32 Loflin M, Earleywine M. A new method of cannabis ingestion: the dangers of dabs? *Addict Behav*. 2014 Oct; 39(10): 1430-3.
- 33 Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet*. 2003; 42(4): 327-60.
- 34 Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, Huestis MA. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. *Drug Test Anal*. 2015 Aug 10. [Epub ahead of print].
- 35 Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Hollister L. Pharmacokinetics and metabolism of delta-9-tetrahydrocannabinol and other cannabinoids with emphasis on man. *Pharmacol Rev* 1986; 38: 21-43.
- 36 Azorlosa JL, Heishman SJ, Stitzer ML, Mahaffey JM. Marijuana smoking: Effect of varying delta-9-tetrahydrocannabinol content and number of puffs. *J Pharmacol Exp Ther* 1992; 261: 114-122.
- 37 Azorlosa JL, Greenwald MK, Stitzer ML. Marijuana smoking: Effects of varying puff volume and breathhold duration. *J Pharmacol Exp Ther* 1995; 272: 560-569.
- 38 Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet*. 2003; 42(4): 327-60.
- 39 Lee D, Bergamaschi MM, Milman G, Barnes AJ, Queiroz RH, Vandrey R, Huestis MA. Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. *J Anal Toxicol*. 2015 Oct; 39(8): 580-7.
- 40 Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. *Clin Chem*. 2013; 59(3): 519-26.
- 41 McPartland JM, Agrawal J, Gleeson D, Heasman K, Glass M. Cannabinoid receptors in invertebrates. *J Evol Biol*. 2006 Mar; 19(2): 366-73.
- 42 Elphick MR. The evolution and comparative neurobiology of endocannabinoid signalling. *Philos Trans R Soc Lond B Biol Sci*. 2012 Dec 5; 367(1607): 3201-15.
- 43 Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. *Handb Exp Pharmacol*. 2005; (168): 299-325.
- 44 Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. *Nature*. 1990 Aug 9; 346(6284): 561-4.
- 45 Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. *J Neurosci*. 1991 Feb; 11(2): 563-83.
- 46 Pazos MR, Núñez E, Benito C, Tolón RM, Romero J. Functional neuroanatomy of the endocannabinoid system. *Pharmacol Biochem Behav*. 2005 Jun; 81(2): 239-47.
- 47 Pertwee RG. Endocannabinoids and Their Pharmacological Actions. *Handb Exp Pharmacol*. 2015; 231: 1-37.
- 48 Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. *Nature*. 1993 Sep 2; 365(6441): 61-5.
- 49 Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, Frank RA. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. *Arch Gen Psychiatry*. 2001 Apr; 58(4): 322-8.

- 
- 50 Kalant, H. Effects of Cannabis and Cannabinoids in the Human Nervous System, in Effects of Drugs in the Human Nervous System, BK Madras and MJ Kuhar eds, Elsevier 2014, ISBN: 978-0-12-418679-8.
- 51 Iger BE, Kim J. Supply and demand for endocannabinoids. *Trends Neurosci.* 2011 Jun; 34(6): 304-15.
- 52 Maccarrone M, Guzmán M, Mackie K, Doherty P, Harkany T. Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. *Nat Rev Neurosci.* 2014 Dec; 15(12): 786-801.
- 53 Foldy, C., Malenka, R. C. & Sudhof, T. C. Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. *Neuron* 2013; 78: 498-509.
- 54 Egan, S. M., Stoyak, S. R., Verrico, C. D. & Lewis, D. A. Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: comparison of schizophrenia and major depressive disorder. *Neuropsychopharmacology* 35, 2060-2071 (2010).
- 55 Minocci, D. et al. Genetic association between bipolar disorder and 524A>C (Leu133Ile) polymorphism of CNR2 gene, encoding for CB2 cannabinoid receptor. *J. Affect. Disord.* 2011; 134: 427-430.
- 56 Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzero P, Proto MC, Di Filippo C, Monteleone F, Canestrelli B, Buonerba G, Bogetto F, Maj M. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. *Pharmacol Res.* 2010 May; 61(5): 400-4.
- 57 Steel RW, Miller JH, Sim DA, Day DJ. Delta-9-tetrahydrocannabinol disrupts hippocampal neuroplasticity and neurogenesis in trained, but not untrained adolescent Sprague-Dawley rats. *Brain Res.* 2014 Feb 22; 1548: 12-9.
- 58 Schiavon AP, Bonato JM, Milani H, Guimarães FS, Weffort de Oliveira RM. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. *Prog Neuropsychopharmacol Biol Psychiatry.* 2016 Jan 4; 64: 27-34.
- 59 Prenderville JA, Kelly ÁM, Downer EJ. The role of cannabinoids in adult neurogenesis. *Br J Pharmacol.* 2015 Aug; 172(16): 3950-63.
- 60 Parmentier-Batteur S, Jin K, Mao XO, Xie L, Greenberg DA. Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. *J Neurosci.* 2002 Nov 15; 22(22): 9771-5.
- 61 Kalant, H. Effects of Cannabis and Cannabinoids in the Human Nervous System, in Effects of Drugs in the Human Nervous System, BK Madras and MJ Kuhar eds, Elsevier 2014, ISBN: 978-0-12-418679-8.
- 62 Izzo AA, Piscitelli F, Capasso R, Aviello G, Romano B, Borrelli F, Petrosino S, Di Marzo V. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. *Br J Pharmacol.* 2009 Sep; 158(2): 451-61.
- 63 Murillo-Rodríguez E. The role of the CB1 receptor in the regulation of sleep. *Prog Neuropsychopharmacol Biol Psychiatry.* 2008 Aug 1; 32(6): 1420-7.
- 64 Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidtkoer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA.* 2015 Jun 23-30; 313(24): 2456-73.
- 65 Akirav I. The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. *Front Behav Neurosci.* 2011 Jun 23; 5: 34.
- 66 Lazary J, Juhasz G, Hunyady L, Bagdy G. Personalized medicine can pave the way for the safe use of CB<sub>1</sub> receptor antagonists. *Trends Pharmacol Sci.* 2011 May; 32(5): 270-80.
- 67 Akirav I. The role of cannabinoids in modulating emotional and non-emotional memory processes in the hippocampus. *Front Behav Neurosci.* 2011 Jun 23; 5: 34.
- 68 Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow ND, Huestis MA, Innis RB. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. *Mol Psychiatry.* 2012 Jun; 17(6): 642-9.
- 69 Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, Toumbourou JW, Degenhardt L, Swift W, Coffey C, Tait RJ, Letcher P, Copeland J, Mattick RP; Cannabis Cohorts Research Consortium. Young adult sequelae of adolescent cannabis use: an integrative analysis. *Lancet Psychiatry.* 2014 Sep; 1(4): 286-93.
- 70 Shollenbarger SG, Price J, Wieser J, Lisdahl K. Poorer frontolimbic white matter integrity is associated with chronic cannabis use, FAAH genotype, and increased depressive and apathy symptoms in adolescents and young adults. *Neuroimage Clin.* 2015 Apr 2; 8: 117-25.

- 
- 71 Choi NG, DiNitto DM, Marti CN, Choi BY. Relationship between marijuana and other illicit drug use and depression/suicidal thoughts among late middle-aged and older adults. *Int Psychogeriatr*. 2015 Nov 6: 1-13. [Epub ahead of print]
- 72 Katona I. Cannabis and Endocannabinoid Signaling in Epilepsy. *Handb Exp Pharmacol*. 2015; 231: 285-316.
- 73 Katona I. Cannabis and Endocannabinoid Signaling in Epilepsy. *Handb Exp Pharmacol*. 2015; 231: 285-316.
- 74 Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. *Neurotherapeutics*. 2015 Aug 18. [Epub ahead of print]
- 75 El Manira A, Kyriakatos A. The role of endocannabinoid signaling in motor control. *Physiology (Bethesda)*. 2010 Aug; 25(4): 230-8.
- 76 Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. *Br J Pharmacol*. 2009 Apr; 156(7): 1029-40.
- 77 Mechoulam R, Parker LA. The endocannabinoid system and the brain. *Annu Rev Psychol*. 2013; 64: 21-47.
- 78 Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S. Effects of endocannabinoid system modulation on cognitive and emotional behavior. *Front Behav Neurosci*. 2011 Sep 13; 5: 57.
- 79 Morena M, Campolongo P. The endocannabinoid system: an emotional buffer in the modulation of memory function. *Neurobiol Learn Mem*. 2014 Jul; 112: 30-43.
- 80 Maccarrone M, Bab I, Biró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A. Endocannabinoid signaling at the periphery: 50 years after THC. *Trends Pharmacol Sci*. 2015 May; 36(5): 277-96.
- 81 Henry RJ, Kerr DM, Finn DP, Roche M. For whom the endocannabinoid tolls: Modulation of innate immune function and implications for psychiatric disorders. *Prog Neuropsychopharmacol Biol Psychiatry*. 2016 Jan 4; 64: 167-80.
- 82 Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. *J Addict Med*. 2011 Mar; 5(1): 1-8.
- 83 Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. *Psychopharmacology (Berl)*. 2006 Nov; 188(4): 425-44.
- 84 Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. *J Addict Med*. 2011 Mar; 5(1): 1-8.
- 85 Hartman RL, Huestis MA. Cannabis effects on driving skills. *Clin Chem*. 2013 Mar; 59(3): 478-92.
- 86 Leirer VO, Yesavage JA, Morrow DG. Marijuana carry-over effects on aircraft pilot performance. *Aviat Space Environ Med*. 1991 Mar; 62(3): 221-7.
- 87 Whitlow CT, Liguori A, Livengood LB, Hart SL, Mussat-Whitlow BJ, Lamborn CM, Laurienti PJ, Porrino LJ. Long-term heavy marijuana users make costly decisions on a gambling task. *Drug Alcohol Depend*. 2004 Oct 5; 76(1): 107-11.
- 88 Wadsworth EJ, Moss SC, Simpson SA, Smith AP. Cannabis use, cognitive performance and mood in a sample of workers. *J Psychopharmacol*. 2006 Jan; 20(1): 14-23.
- 89 Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. *Clin Chem*. 2013 Mar; 59(3): 519-26.
- 90 Bosson MG, Jager G, Bhattacharyya S, Allen P. Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. *Curr Pharm Des*. 2014; 20(13): 2114-25.
- 91 Pagliaccio D, Barch DM, Bogdan R, Wood PK, Lynskey MT, Heath AC, Agrawal A. Shared Predisposition in the Association Between Cannabis Use and Subcortical Brain Structure. *JAMA Psychiatry*. 2015 Aug 26. [Epub print]
- 92 Insanity from hasheesh. *J Mental Sci*. 1903; 49: 96-110.
- 93 Wilkinson ST, Radhakrishnan R, D'Souza DC. Impact of Cannabis Use on the Development of Psychotic Disorders. *Curr Addict Rep*. 2014 Jun 1; 1(2): 115-128.
- 94 Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. *J Psychopharmacol*. 2005 Mar; 19(2): 187-94.
- 95 Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Prognosis of schizophrenia in persons with and without a history of cannabis use. *Psychol Med*. 2014 Sep; 44(12): 2513-21.
- 96 Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: asystematic review. *Lancet*. 2007 Jul 28; 370(9584): 319-28.

- 
- 97 Di Forti M, Marconi A, Carra E, Fraietta S, Trotta A, Bonomo M, Bianconi F, Gardner-Sood P, O'Connor J, Russo M, Stilo SA, Marques TR, Mondelli V, Dazzan P, Pariante C, David AS, Gaughran F, Atakan Z, Iyegbe C, Powell J, Morgan C, Lynskey M, Murray RM. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *Lancet Psychiatry*. 2015 Mar; 2(3): 233-8.
- 98 Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, MacCabe JH, Murray RM. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. *Schizophr Bull*. 2014 Nov; 40(6): 1509-17.
- 99 D'Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. *Eur Arch Psychiatry Clin Neurosci*. 2009 Oct; 259(7): 413-31.
- 100 Radhakrishnan R, Wilkinson ST, D'Souza DC, Gone to Pot - A Review of the Association between Cannabis and Psychosis, *Front Psychiatry*. 2014 May 22; 5: 54.
- 101 Di Forti M, Marconi A, Carra E, et al. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. *Lancet Psychiatry* 2015; 2: 233-8.
- 102 Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *N Engl J Med*. 2014 Jun 5; 370(23): 2219-27.
- 103 Gates P, Jaffe A, Copeland J. Cannabis smoking and respiratory health: consideration of the literature. *Respirology* 2014; 19: 655-62.
- 104 Roth MD, Arora A, Barsky SH, Kleerup EC, Simmons M, Tashkin DP. Airway inflammation in young marijuana and tobacco smokers. *Am J Respir. Crit. Care Med*. 1998; 157: 928-37.
- 105 Fligiel SEG, Roth MD, Kleerup EC, Barsky SH, Simmons MS, Tashkin DP. Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. *Chest* 1997; 112: 319-26.
- 106 Johnston, L. D., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E. & Miech, R. A. (2015). Monitoring the Future national survey results on drug use, 1975-2014: Volume 2, College students and adults ages 19-55. Ann Arbor: Institute for Social Research, The University of Michigan. Chapter 8 ([http://www.monitoringthefuture.org/pubs/monographs/mtf-vol2\\_2014.pdf](http://www.monitoringthefuture.org/pubs/monographs/mtf-vol2_2014.pdf), accessed 11 December 2015).
- 107 Pletcher MJ, Vittinghoff E, Kalhan R, Richman J, Safford M, Sidney S, Lin F, Kertesz S. Association between marijuana exposure and pulmonary function over 20 years. *JAMA*. 2012 Jan 11; 307(2): 173-81.
- 108 Owen KP, Sutter ME, Albertson TE. Marijuana: respiratory tract effects. *Clin Rev Allergy Immunol*. 2014 Feb; 46(1): 65-81.
- 109 Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. *Am J Cardiol*. 2014 Jan 1; 113(1): 187-90.
- 110 Kramer JL. Medical marijuana for cancer. *CA Cancer J Clin*. 2015; 65: 109-122.
- 111 Bowles DW, O'Bryant CL, Ross Camidge D, Jimeno A. The intersection between cannabis and cancer in the United States. *Critical Reviews in Oncology/Hematology*, Vol 83, 2012, Pages 1-10.
- 112 de Carvalho MF, Dourado MR, Fernandes IB, Araújo CT, Mesquita AT, Ramos-Jorge ML. Head and neck cancer among marijuana users: A meta-analysis of matched case-control studies. *Arch Oral Biol*. 2015 Sep 15; 60(12): 1750-1755.
- 113 Lacson JC, Carroll JD, Tuazon E, Castela EJ, Bernstein L, Cortessis VK Population-based case-control study of recreational drug use and testis cancer risk confirms an association between cannabis use and nonseminoma risk. *Cancer*. 2012 118(21): 5374-83.
- 114 de Carvalho MF, Dourado MR, Fernandes IB, Araújo CT, Mesquita AT, Ramos-Jorge ML. Head and neck cancer among marijuana users: A meta-analysis of matched case-control studies. *Arch Oral Biol*. 2015 Dec; 60(12): 1750-5.
- 115 Huang YH, Zhang ZF, Tashkin DP, Feng B, Straif K, Hashibe M. An epidemiologic review of marijuana and cancer: an update. *Cancer Epidemiol Biomarkers Prev*. 2015 Jan; 24(1): 15-31.
- 116 Berthiller J, Straif K, Boniol M, Voirin N, Benhaïm-Luzon V, Ayoub WB, Dari I, Laouamri S, Hamdi-Cherif M, Bartal M, Ayed FB, Sasco AJ. Cannabis smoking and risk of lung cancer in men: a pooled analysis of three studies in Maghreb. *J Thorac Oncol*. 2008 Dec; 3(12): 1398-403.
- 117 Aldington S, Harwood M, Cox B, Weatherall M, Beckert L, Hansell A, Pritchard A, Robinson G, Beasley R; Cannabis and Respiratory Disease Research Group. Cannabis use and risk of lung cancer: a case-control study. *Eur Respir J*. 2008 Feb; 31(2): 280-6.
- 118 Gurney J, Shaw C, Stanley J, Signal V, Sarfati D. Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. *BMC Cancer*. 2015 Nov 11; 15(1): 897. doi: 10.1186/s12885-015-1905-6.

- 
- 119 Marks MA, Chaturvedi AK, Kelsey K, Straif K, Berthiller J, Schwartz SM, Smith E, Wyss A, Brennan P, Olshan AF, Wei Q, Sturgis EM, Zhang ZF, Morgenstern H, Muscat J, Lazarus P, McClean M, Chen C, Vaughan TL, Wunsch-Filho V, Curado MP, Koifman S, Matos E, Menezes A, Daudt AW, Fernandez L, Posner M, Boffetta P, Lee YC, Hashibe M, D'Souza G. Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. *Cancer Epidemiol Biomarkers Prev.* 2014 Jan; 23(1): 160-71.
- 120 Efrid JT, Friedman GD, Sidney S, Klatsky A, Habel LA, Udaltsova NV, Van den Eeden S, Nelson LM. The risk for malignant primary adult-onset glioma in a large, multiethnic, managed-care cohort: cigarette smoking and other lifestyle behaviors. *J Neurooncol.* 2004 May; 68(1): 57-69.
- 121 du Plessis SS, Agarwal A, Syriac A. Marijuana, phytocannabinoids, the endocannabinoid system, and male fertility. *J Assist Reprod Genet.* 2015 Aug 16. [Epub ahead of print]
- 122 Iacopetti CL, Packer CD. Cannabinoid hyperemesis syndrome: a case report and review of pathophysiology. *Clin Med Res.* 2014 Sep; 12(1-2): 65-7.
- 123 Alaniz VI, Liss J, Metz TD, Stickrath E. Cannabinoid hyperemesis syndrome: a cause of refractory nausea and vomiting in pregnancy. *Obstet Gynecol.* 2015 Jun; 125(6): 1484-6.
- 124 Drug Abuse Warning Network, 2011: National estimates of drug-related emergency department visits. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2011 (<http://www.samhsa.gov/data/2k13/DAWN2k11ED/DAWN2k11ED.htm>, accessed 11 December 2015).
- 125 Liakoni E, Dolder PC, Rentsch K, Liechti ME. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland. *Swiss Med Wkly.* 2015 Jul 28; 145: w14166.
- 126 Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, Sedefov R, Dargan PI; Euro-DEN Research Group. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN). *Clin Toxicol (Phila).* 2015 Nov; 53(9): 893-900.
- 127 Kaar SJ, Gao CX, Lloyd B, Smith K, Lubman DI. Trends in cannabis-related ambulance presentations from 2000 to 2013 in Melbourne, Australia. *Drug Alcohol Depend.* 2015 Oct 1; 155: 24-30.
- 128 Callaghan RC, Cunningham JK, Verdichevski M, Sykes J, Jaffer SR, Kish SJ. All-cause mortality among individuals with disorders related to the use of methamphetamine: a comparative cohort study. *Drug Alcohol Depend.* 2012 125(3): 290-4.
- 129 Sonon KE, Richardson GA, Cornelius JR, Kim KH, Day NL. Prenatal marijuana exposure predicts marijuana use in young adulthood. *Neurotoxicol Teratol.* 2015 Jan-Feb; 47: 10-5.
- 130 Calvigioni D, Hurd YL, Harkany T, Keimpema E. Neuronal substrates and functional consequences of prenatal cannabis exposure. *Eur Child Adolesc Psychiatry.* 2014 Oct; 23(10): 931-41.
- 131 Noland, J. S., Singer, L. T., Short, E. J., Minnes, S., Arendt, R. E., Lester Kirchner, H., et al. Prenatal drug exposure and selective attention in preschoolers. *Neurotoxicol Teratol* 2005; 27(3), 429-438.
- 132 Goldschmidt, L., Day, N. L., & Richardson, G. A. Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicol Teratol* 2000; 22(3), 325-336.
- 133 Goldschmidt, L., Richardson, G. A., Cornelius, M. D., & Day, N. L. Prenatal marijuana and alcohol exposure and academic achievement at age 10. *Neurotoxicol Teratol* 2004; 26(4), 521-532.
- 134 Goldschmidt, L., Richardson, G. A., Willford, J., & Day, N. L. Prenatal marijuana exposure and intelligence test performance at age 6. *J Am Acad Child Adolesc Psychiatry* 2008; 47(3), 254-263.
- 135 Day, N. L., Leech, S. L., & Goldschmidt, L. The effects of prenatal marijuana exposure on delinquent behaviors are mediated by measures of neurocognitive functioning. *Neurotoxicol Teratol* 2011; 33(1), 129-136.
- 136 Fried, P., Watkinson, B., & Gray, R. Neurocognitive consequences of marihuana—a comparison with pre-drug performance. *Neurotoxicol Teratol* 2005; 27(2), 231-239.
- 137 Pope, H. G., Gruber, A. J., Hudson, J. I., Cohane, G., Huestis, M. A., & Yurgelun-Todd, D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? *Drug Alcohol Depend* 2003; 69(3), 303-310.



- 
- 138 Gruber, S. A., Sagar, K. A., Dahlgren, M. K., Racine, M., & Lukas, S. E. . Age of onset of marijuana use and executive function. *Psychol Addict Behav* 2012; 26(3), 496.
- 139 Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? *Drug Alcohol Depend*. 2003 Apr 1; 69(3): 303-10.
- 140 Moffitt TE, Meier MH, Caspi A, Poulton R. Reply to Rogeberg and Daly: No evidence that socioeconomic status or personality differences confound the association between cannabis use and IQ decline. *Proc Natl Acad Sci U S A*. 2013 Mar 12; 110(11): E980-2.
- 141 Solowij, N., Jones, K. A., Rozman, M. E., Davis, S. M., Ciarrochi, J., Heaven, P. C., et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. *Psychopharmacology (Berl)* 2011; 216(1), 131-144.
- 142 Lorenzetti V, Solowij N, Fornito A, Lubman DI, Yücel M. The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. *Curr Pharm Des*. 2014; 20(13): 2138-67.
- 143 Bossong MG, Jager G, Bhattacharyya S, Allen P. Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. *Curr Pharm Des*. 2014; 20(13): 2114-25.
- 144 Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. *Curr Pharm Des*. 2014; 20(13): 2186-93.
- 145 Churchwell JC, Lopez-Larson M, Yurgelun-Todd DA. Altered frontal cortical volume and decision making in adolescent cannabis users. *Front Psychol*. 2010; Dec 14; 1: 225.
- 146 Lopez-Larson, M. P., Bogorodzki, P., Rogowska, J., McGlade, E., King, J. B., Terry, J., et al.. Altered prefrontal and insular cortical thickness in adolescent marijuana users. *Behav Brain Res* 2011; 220(1), 164-172.
- 147 Ashtari M, Avants B, Cyckowski L, Cervellione KL, Roofeh D, Cook P, Gee J, Sevy S, Kumra S. Medial temporal structures and memory functions in adolescents with heavy cannabis use. *J Psychiatr Res*. 2011 Aug; 45(8): 1055-66.
- 148 Lorenzetti, V., Solowij, N., Fornito, A., Lubman, D., & Yücel, M. The association between regular cannabis exposure and alterations of human brain morphology: an updated review of the literature. *Curr Pharm Des* 2014; 20(13), 2138-2167.
- 149 Cheetham A, Allen NB, Whittle S, Simmons JG, Yücel M, Lubman DI. Orbitofrontal volumes in early adolescence predict initiation of cannabis use: a 4-year longitudinal and prospective study. *Biol Psychiatry*. 2012 Apr 15; 71(8): 684-92.
- 150 Schweinsburg AD, Brown SA, Tapert SF. The influence of marijuana use on neurocognitive functioning in adolescents. *Curr Drug Abuse Rev* 2008; 1: 99-111.
- 151 Bray JW, Zarkin GA, Ringwalt C, Qi J. The relationship between marijuana initiation and dropping out of high school. *Health Econ*. 2000; 9: 9-18.
- 152 Lynskey M, Hall W. The effects of adolescent cannabis use on educational attainment: a review. *Addiction* 2000; 95: 1621-30.
- 153 Verweij KJ, Huizink AC, Agrawal A, Martin NG, Lynskey MT. Is the relationship between early-onset cannabis use and educational attainment causal or due to common liability? *Drug Alcohol Depend* 2013; 133: 580-6.
- 154 Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. *Soc Psychiatry Psychiatr Epidemiol*. 2015 Sep; 50(9): 1317-26.
- 155 Fergusson DM, Boden JM. Cannabis use and later life outcomes. *Addiction*. 2008 Jun; 103(6): 969-76.
- 156 Brook JS, Lee JY, Finch SJ, Seltzer N, Brook DW. Adult work commitment, financial stability, and social environment as related to trajectories of marijuana use beginning in adolescence. *Subst Abuse* 2013; 34: 298-305.
- 157 Ehrenreich H, Nahapetyan L, Orpinas P, Song X. Marijuana Use from Middle to High School: Co-occurring Problem Behaviors, Teacher-Rated Academic Skills and Sixth-Grade Predictors. *J Youth Adolesc*. 2015 Oct; 44(10): 1929-40.
- 158 Bagot KS, Milin R, Kaminer Y. Adolescent Initiation of Cannabis Use and Early-Onset Psychosis. *Subst Abuse*. 2015 Mar 16: 0. [Epub ahead of print]
- 159 Wilkinson ST, Radhakrishnan R, D'Souza DC. Impact of Cannabis Use on the Development of Psychotic Disorders. *Curr Addict Rep*. 2014 Jun 1; 1(2): 115-128.
- 160 Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: a systematic review and meta-analysis. *J Affect Disord*. 2015 Jan 15; 171: 39-47.
- 161 Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. *BMJ*. 2002 Nov 23; 325(7374): 1212-3.

- 
- 162 Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, Marconi A, La Cascia C, Reis Marques T, Pariante C, Dazzan P, Mondelli V, Paparelli A, Kolliakou A, Prata D, Gaughran F, David AS, Morgan C, Stahl D, Khondoker M, MacCabe JH, Murray RM. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. *Schizophr Bull.* 2014Nov; 40(6): 1509-17.
- 163 Bechtold J, Simpson T, White HR, Pardini D. Chronic adolescent marijuana use as a risk factor for physical and mental health problems in young adult men. *Psychol Addict Behav.* 2015 Sep; 29(3): 552-63.
- 164 Shakoor S, Zavos HM, McGuire P, Cardno AG, Freeman D, Ronald A. Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors. *Psychiatry Res.* 2015 Jun30; 227(2-3): 144-51.
- 165 Source: SAMHSA, Office of Applied Studies, National Household Survey on Drug Abuse, 2000, updated 2008
- 166 Mayet A, Legleye S, Falissard B, Chau N. Cannabis use stages as predictors of subsequent initiation with other illicit drugs among French adolescents: use of a multi-state model. *Addict Behav.* 2012 Feb; 37(2): 160-6.
- 167 Secades-Villa R, Garcia-Rodríguez O, Jin CJ, Wang S, Blanco C. Probability and predictors of the cannabis gateway effect: a national study. *Int J Drug Policy.* 2015; 26(2): 135-142.
- 168 Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, Statham DJ, Martin NG Escalation of drug use in early-onset cannabis users vs co-twin controls. *JAMA.* 2003 Jan 22-29; 289(4): 427-33.
- 169 Agrawal A, Neale MC, Prescott CA, Kendler KS. A twin study of early cannabis use and subsequent use and abuse/ dependence of other illicit drugs. *Psychol Med* 2004; 34: 1227-37.
- 170 Hartman RL, Huestis MA. Cannabis effects on driving skills. *Clin Chem.* 2013 Mar; 59(3): 478-92.
- 171 Drug-impaired driving: a guide for what states can do. Washington, Foundation for Advancing Alcohol Responsibility and Governors Highway Safety Association, 2015([http://www.ghsa.org/html/files/pubs/GHSA\\_DruggedDriving2015\\_R5\\_LoRes.pdf](http://www.ghsa.org/html/files/pubs/GHSA_DruggedDriving2015_R5_LoRes.pdf), accessed 11 December 2015).
- 172 Asbridge M, Mann R, Cusimano MD, Trayling C, Roerecke M, Tallon JM, Whipp A, Rehm J. Cannabis and traffic collision risk: findings from a case-crossover study of injured drivers presenting to emergency departments. *Int J Public Health.* 2014 Apr; 59(2): 395-404.
- 173 Acar F, Asirdizer M, Aker RG, Kucukibrahimoglu EE, Ates I, Erol Y, Sahin A. A review of suspected cases of driving under the influence of drugs (DUID) involved in traffic accidents in Istanbul (Turkey). *J Forensic Leg Med.* 2013; 20(6): 626-31
- 174 Hels T, Lyckegaard A, Simonsen KW, Steentoft A, Bernhoft IM. Risk of severe driver injury by driving with psychoactive substances. *Accid Anal Prev.* 2013 Oct; 59: 346-56.
- 175 Legrand SA, Silverans P, de Paepe P, Buylaert W, Verstraete AG. Presence of psychoactive substances in injured Belgian drivers. *Traffic Inj Prev.* 2013; 14(5): 461-8.
- 176 Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, Gaffney G, Huestis MA. Cannabis effects on driving lateral control with and without alcohol. *Drug Alcohol Depend.* 2015 Sep 1; 154: 25-37.
- 177 Wadsworth EJ, Moss SC, Simpson SA, Smith AP. Cannabis use, cognitive performance and mood in a sample of workers. *J Psychopharmacol.* 2006 Jan; 20(1): 14-23.
- 178 Compton WM, Gfroerer J, Conway KP, Finger MS. Unemployment and substance outcomes in the United States 2002-2010. *Drug Alcohol Depend.* 2014; 142: 350-353.
- 179 Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, Gaffney G, Huestis MA. Cannabis effects on driving lateral control with and without alcohol. *Drug Alcohol Depend.* 2015 Sep 1; 154: 25-37.
- 180 Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, Huestis MA. Controlled Cannabis Vaporizer administration: Blood and Plasma Cannabinoids with and without Alcohol. *Clin Chem.* 2015 Jun; 61(6): 850-69.
- 181 Dubois S, Mullen N, Weaver B, Bédard M. The combined effects of alcohol and cannabis on driving: Impact on crash risk. *Forensic Sci Int.* 2015 Mar; 248: 94-100.
- 182 Goldsmith RS, Targino MC, Fanciullo GJ, Martin DW, Hartenbaum NP, White JM, Franklin P. Medical marijuana in the workplace: challenges and management options for occupational physicians. *J Occup Environ Med.* 2015 May; 57(5): 518-25.
- 183 Phillips JA, Holland MG, Baldwin DD, Gifford-Meuleveld L, Mueller KL, Perkison B, Upfal M, Dreger M. Marijuana in the Workplace: Guidance for Occupational Health Professionals and Employers: Joint Guidance Statement of the American Association of Occupational Health Nurses and the American College of Occupational and Environmental Medicine. *Workplace Health Saf.* 2015 Apr; 63(4): 139-64.

- 
- 184 Arria AM, Caldeira KM, Bugbee BA, Vincent KB, O'Grady KE. The academic consequences of marijuana use during college. *Psychol Addict Behav.* 2015 Sep; 29(3): 564-75.
- 185 Martinez JA, Roth MG, Johnson DN, Jones JA. How Robustly Does Cannabis Use Associate to College Grades? Findings From Two Cohorts. *J Drug Educ.* 2015; 45(1): 56-67.
- 186 Caldeira KM, Arria AM, O'Grady KE, Vincent KB, Wish ED. The occurrence of cannabis use disorders and other cannabis- related problems among first-year college students. *Addict Behav.* 2008 Mar; 33(3): 397-411.
- 187 World Drug Report 2015. Vienna, UN Office on Drugs and Crime, 2015  
(<https://www.unodc.org/unodc/en/frontpage/2015/June/2015-world-drug-report-finds-drug-use-stable--access-to-drug-and-hiv-treatment-still-low.html>, accessed 11 December 2015).
- 188 Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: recommendations and rationale. *Am J Psychiatry.* 2013 Aug; 170(8): 834-51.
- 189 Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J, Budney AJ. Quantifying the clinical significance of cannabis withdrawal. *PLoS One.* 2012; 7(9): e44864.
- 190 Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. *Drug Alcohol Depend.* 2011 Dec 1; 119(1-2): 123-9.
- 191 Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: recommendations and rationale. *Am J Psychiatry.* 2013 Aug; 170(8): 834-51.
- 192 Levin KH; Copersino ML; Heishman SJ; Liu F; Kelly DL; Boggs DL; Gorelick DA: Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. *Drug Alcohol Depend* 2010; 111: 120-127.
- 193 Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and significance of cannabis withdrawal. *J Abnorm Psychol.* 2003 Aug; 112(3): 393-402.
- 194 Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J, Budney AJ. Quantifying the clinical significance of cannabis withdrawal. *PLoS One.* 2012; 7(9): e44864.
- 195 Smith PH, Homish GG, Leonard KE, Collins RL. Marijuana withdrawal and aggression among a representative sample of U.S. marijuana users. *Drug Alcohol Depend.* 2013 Sep 1; 132(1-2): 63-8.
- 196 Greene MC, Kelly JF. The prevalence of cannabis withdrawal and its influence on adolescents' treatment response and outcomes: a 12-month prospective investigation. *J Addict Med.* 2014 Sep-Oct; 8(5): 359-67.
- 197 Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, et al. The global epidemiology and contribution of cannabis use and dependence to the global burden of disease: results from the GBD 2010 study. *PLoS One.* 2013; 8(10): e76635.
- 198 World Drug Report 2012. Vienna, UN Office on Drugs and Crime, 2012  
([http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR\\_2012\\_web\\_small.pdf](http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf), accessed 11 December 2015).
- 199 Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. Rockville, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, US Department of Health and Human Services, 2015 (<http://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf>, accessed 11 December 2015).
- 200 European Monitoring Centre for Drugs and Drug Addiction. Website, (<http://www.emcdda.europa.eu/countries>, accessed 11 December 2015).
- 201 Cannabis Drug Profile. European Monitoring Centre for Drugs and Drug Addiction. Website  
(<http://www.emcdda.europa.eu/publications/drug-profiles/cannabis>, accessed 11 December 2015).
- 202 Miech RA, Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE. Monitoring Future National Survey Results on Drug Use 1975-2014. Ann Arbor, Institute for Social Research, The University of Michigan, 2015 ([http://www.monitoringthefuture.org/pubs/monographs/mtf-vol1\\_2014.pdf](http://www.monitoringthefuture.org/pubs/monographs/mtf-vol1_2014.pdf), accessed 11 December 2015).
- 203 Johnston L D, O'Malley PM, Miech RA, Bachman, JG, Schulenberg JE. Monitoring the Future national survey results on drug use: 1975-2014: Overview, key findings on adolescent drug use. Ann Arbor, Institute for Social Research, The University of Michigan, 2015  
(<http://www.monitoringthefuture.org/pubs/monographs/mtf-overview2014.pdf>, accessed 11 December 2015).

- 
- 204 Lopez-Quintero C, Pérez de los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). *Drug Alcohol Depend* 2011; 115: 120-30.
- 205 Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet* 2009; 374: 1383-91.
- 206 Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan J, Smith SM, Huang B, Grant, BF. Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. *JAMA Psychiatry*. doi: 10.1001/jamapsychiatry.2015.1858 (published online October 21, 2015).
- 207 The Teds Report: Substance Abuse Treatment Admissions Aged 15 to 17. Rockville, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, US Department of Health and Human Services, 2012 ([http://www.samhsa.gov/data/2k12/TEDS\\_061/TEDS\\_061\\_LateAdolescents\\_2012.htm](http://www.samhsa.gov/data/2k12/TEDS_061/TEDS_061_LateAdolescents_2012.htm), accessed 11 December 2015).
- 208 Caldeira KM, O'Grady KE, Vincent KB, Arria AM. Marijuana use trajectories during the post-college transition: health outcomes in young adulthood. *Drug Alcohol Depend*. 2012 Oct 1; 125(3): 267-75.
- 209 Arria AM, Caldeira KM, Bugbee BA, Vincent KB, O'Grady KE. The academic consequences of marijuana use during college. *Psychol Addict Behav*. 2015 Sep; 29(3): 564-75.
- 210 The Teds Report: Age of Substance Use Initiation among Treatment Admissions Aged 18 to 30. Rockville, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, US Department of Health and Human Services, 2014 ([http://www.samhsa.gov/data/sites/default/files/WebFiles\\_TEDS\\_SR142\\_AgeatInit\\_07-10-14/TEDS-SR142-AgeatInit-2014.htm](http://www.samhsa.gov/data/sites/default/files/WebFiles_TEDS_SR142_AgeatInit_07-10-14/TEDS-SR142-AgeatInit-2014.htm), accessed 11 December 2015).
- 211 Rotermann M, Langlois K. Prevalence and correlates of marijuana use in Canada, 2012. *Health Rep*. 2015 Apr 15; 26(4): 10-5.
- 212 Canadian Drug Summary: Cannabis. Ottawa, Canadian Centre on Substance Abuse, 2015 (<http://www.ccsa.ca/Resource%20Library/CCSA-Canadian-Drug-Summary-Cannabis-2015-en.pdf>, accessed 11 December 2015).
- 213 National Drug Strategy Household Survey detailed report 2013. Canberra, Australian Institute of Health and Welfare, 2014 (<http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=60129549848>, accessed 11 December 2015).
- 214 Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. *N Engl J Med*. 2014 Jun 5; 370(23): 2219-27.
- 215 Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. *Drug Test Anal*. 2014 Jan-Feb; 6(1-2): 39-45.
- 216 Hall W, Degenhardt L. High potency cannabis: a risk factor for dependence, poor psychosocial outcomes, and psychosis. *BMJ*. 2015 Mar 4; 350: h1205.
- 217 Burgdorf JR, Kilmer B, Pacula RL. Heterogeneity in the composition of cannabis seized in California. *Drug Alcohol Depend*. 2011 Aug 1; 117(1): 59-61.
- 218 Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011 Aug; 163(7): 1344-64.
- 219 Radwan MM, ElSohly MA, El-Alfy AT, Ahmed SA, Slade D, Husni AS, Manly SP, Wilson L, Seale S, Cutler SJ, Ross SA. Isolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa. *J Nat Prod*. 2015 Jun 26; 78(6): 1271-6.
- 220 Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci*. 2009 Oct; 30(10): 515-27.
- 221 Moir D, Rickert WS, Levasseur G, Larose Y, Maertens R, White P, Desjardins S. A comparison of mainstream and sidestream cannabis and tobacco cigarette smoke produced under two machine smoking conditions. *Chem Res Toxicol*. 2008 Feb; 21(2): 494-502.
- 222 Sullivan N, Elzinga S, Raber JC. Determination of pesticide residues in cannabis smoke. *J Toxicol*. 2013; 2013: 378168.
- 223 Martyny JW, Serrano KA, Schaeffer JW, Van Dyke MV. Potential exposures associated with indoor cannabis growing operations. *J Occup Environ Hyg*. 2013; 10(11): 622-39.
- 224 Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol*. 2011 Aug; 163(7): 1344-64.
- 225 Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. *Neuropsychopharmacology*. 2013 Sep; 38(10): 1984-92.

- 
- 226 Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. *J Acquir Immune Defic Syndr*. 2007 Aug 15; 45(5): 545-54.
- 227 Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of cannabis use. *N Engl J Med*. 2014 Jun 5; 370(23): 2219-27.
- 228 Azorlosa JL, Greenwald MK, Stitzer ML. Cannabis smoking: Effects of varying puff volume and breathhold duration. *J Pharmacol Exp Ther* 1995; 272: 560-569.
- 229 Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clin Pharmacokinet*. 2003; 42(4): 327-60.
- 230 Lee D, Bergamaschi MM, Milman G, Barnes AJ, Queiroz RH, Vandrey R, Huestis MA. Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. *J Anal Toxicol*. 2015 Oct; 39(8): 580-7.
- 231 Kempker JA, Honig EG, Martin GS. The effects of cannabis exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. *Ann Am Thorac Soc*. 2015 Feb; 12(2): 135-41.
- 232 Hancox RJ, Shin HH, Gray AR, Poulton R, Sears MR. Effects of quitting cannabis on respiratory symptoms. *Eur Respir J*. 2015 Jul; 46(1): 80-7.
- 233 Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, Orlov I, Cox B. Cannabis smoking and lung cancer risk: pooled analysis in the International Lung Cancer Consortium. *Int J Cancer* 2015; 136: 894-903.
- 234 Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain*. 2013 Feb; 14(2): 136-48.
- 235 Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. *J Pain Palliat Care Pharmacother*. 2014 Sep; 28(3): 216-25.
- 236 Hartman RL, Brown TL, Milavetz G, Spurgin A, Gorelick DA, Gaffney G, Huestis MA. Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. *Drug Test Anal*. 2015 Aug 10. [Epub ahead of print]
- 237 Fishedick J, Van Der Kooy F, Verpoorte R. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. *Chem Pharm Bull (Tokyo)*. 2010 Feb; 58(2): 201-7.
- 238 Hall WD, Pacula RL. Cannabis Use and Dependence: Public Health and Public Policy. Cambridge, UK: Cambridge University Press; 2003.
- 239 Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason BJ. Effects of chronic, heavy cannabis use on executive functions. *J Addict Med*. 2011 Mar; 5(1): 9-15.
- 240 Ono M, Ogilvie JM, Wilson JS, Green HJ, Chambers SK, Ownsworth T, Shum DH. A meta-analysis of cognitive impairment and decline associated with adjuvant chemotherapy in women with breast cancer. *Front Oncol*. 2015 Mar 10; 5: 59. PMID: PMC4354286.
- 241 Joly F, Giffard B, Rigal O, De Ruiter MB, Small BJ, Dubois M, LeFel J, Schagen SB, Ahles TA, Wefel JS, Vardy JL, Pancré V, Lange M, Castel H. Impact of Cancer and Its Treatment on Cognitive Function: Advances in Research from the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012. *J Pain Symptom Manage*. 2015 Sep 4. pii: S0885-3924(15)00451-0. PMID: 26344551.
- 242 Pavisian B, MacIntosh BJ, Szilagyi G, Staines RW, O'Connor P, Feinstein A. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. *Neurology*. 2014 May 27; 82(21): 1879-87.
- 243 Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. *Addiction*. 1998 Jun; 93(6): 837-46.
- 244 Hartman RL, Brown TL, Milavetz G, Spurgin A, Pierce RS, Gorelick DA, Gaffney G, Huestis MA. Cannabis effects on driving lateral control with and without alcohol. *Drug Alcohol Depend*. 2015 Sep 1; 154: 25-37.
- 245 Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. *Am J Cardiol*. 2014 Jan 1; 113(1): 187-90.
- 246 Hazekamp et al. Hazekamp, A., Ware, M.A., Muller-Vahl, K.R., Abrams, D. & Grotenhermen, F. The medicinal use of cannabis and cannabinoids—an international cross-sectional survey on administration forms. *J Psychoactive Drugs* 45, 199-210 (2013).
- 247 Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of cannabis for the treatment of commonly state-approved medical and psychiatric disorders. *Addict Sci Clin Pract*. 2015 Apr 21; 10(1): 10.
- 248 Langhorst J, Wulfert H, Lauche R, Klose P, Cramer H, Dobos GJ, Korzenik J. Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases. *J Crohns Colitis*. 2015 Jan; 9(1): 86-106.

- 
- 249 Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidtkoer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA*. 2015 Jun 23-30; 313(24): 2456-73.
- 250 Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology*. 2007 Feb 13; 68(7): 515-21.
- 251 Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical cannabis in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2014 Apr 29; 82(17): 1556-63.
- 252 Gloss D, Vickrey B. Cannabinoids for epilepsy. *Cochrane Database Syst Rev*. 2014 Mar 5; 3: CD009270.
- 253 Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. *PLoS One*. 2010 Dec 28; 5(12): e14433.
- 254 Benbadis SR, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Smith A, Zesiewicz T. Medical cannabis in neurology. *Expert Rev Neurother*. 2014 ec; 14(12): 1453-65.
- 255 Pryce G, Baker D. Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. *Handb Exp Pharmacol*. 2015; 231: 213-31.
- 256 Compston A, Coles Multiple sclerosis. *Lancet* 2002; 359: 1221-1231.
- 257 Compston A, Coles A Multiple sclerosis. *Lancet* 2008; 372: 1502-1517.
- 258 Kurtzke JF Epidemiologic evidence for multiple sclerosis as an infection. *Clin Microbiol Rev*. 1993; 6: 382-427
- 259 Confavreux C, Vukusic S Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. *Clin Neurol Neurosurg*. 2006; 108: 327-332. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. *N Engl J Med*. 2000; 343: 1430-1438.
- 260 De Jesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson AM, Finch NA, Flynn H, Adamson J, Kouri N, Wojtas A, Sengdy P, Hsiung GY, Karydas A, Seeley WW, Josephs KA, Coppola G, Geschwind DH, Wszolek ZK, Feldman H, Knopman DS, Petersen RC, Miller BL, Dickson DW, Boylan KB, Graff-Radford NR, Rademakers R Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. *N Engl J Med* 343: 1430-1438.
- 261 Chong, M.S., Wolff, K., Wise, K., Tanton, C., Winstock, A., Silber, E., 2006. Cannabis use in patients with multiple sclerosis. *Mult. Scler*. 12 (5), 646-651.
- 262 Hulst, H.E., Steenwijk, M.D., Versteeg, A., Pouwels, P.J., Vrenken, H., Uitdehaag, B.M., Polman, C.H., Geurts, J.J., Barkhof, F., Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions. *Neurology* 2013; 80 (11), 1025-1032.
- 263 Lansley, J., Mataix-Cols, D., Grau, M., Radua, J., Sastre-Garriga, J., Localized grey matter atrophy in multiple sclerosis: a meta-analysis of voxel-based morphometry studies and associations with functional disability. *Neurosci. Biobehav. Rev*. 2013; 37 (5), 819-830.
- 264 Ghaffar, O., Feinstein, A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. *Neurology* 2008; 71 (3), 164-169.
- 265 Honarmand, K., Tierney, M.C., O'Connor, P., Feinstein, A. Effects of cannabis on cognitive function in patients with multiple sclerosis. *Neurology* 2011; 76 (13), 1153-1160.
- 266 Pavisian, B., MacIntosh, B.J., Szilagyi, G., Staines, R.W., O'Connor, P., Feinstein, A. Effects of cannabis on cognition in patients with MS: a psychometric and MRI study. *Neurology* 2014; 82 (21), 1879-1887.
- 267 Romero K, Pavisian B, Staines WR, Feinstein A. Multiple sclerosis, cannabis, and cognition: A structural MRI study. *Neuroimage Clin*. 2015 Apr 9; 8: 140-7.
- 268 Centonze D, Bari M, Rossi S, Prosperetti C, Furlan R, Fezza F, De Chiara V, Battistini L, Bernardi G, Bernardini S, Martino G, Maccarrone M (2007) The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis. *Brain* 130: 2543-2553.
- 269 Lourbopoulos A, Grigoriadis N, Lagoudaki R, Touloumi O, Polyzoidou E, Mavromatis I, Tascos N, Breuer A, Ovadia H, Karussis D, Shohami E, Mechoulam R, Simeonidou C. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. *Brain Res* 2011; 1390: 126-141.
- 270 Cabranes A, Venderova K, de Lago E, Fezza F, Sánchez A, Mestre L, Valenti M, García-Merino A, Ramos JA, Di Marzo V, Fernández-Ruiz J. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. *Neurobiol Dis*. 2005; 20: 207-217.

- 
- 271 Webb M, Luo L, Ma JY, Tham CS. Genetic deletion of fatty acid amide hydrolase results in improved long-term outcome in chronic autoimmune encephalitis. *Neurosci Lett*. 2008; 439: 106-110.
- 272 Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. *Mol Pharmacol*. 2000 May; 57(5): 1045-50.
- 273 Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. *Eur Neurol*. 2014; 71: 271-279.
- 274 Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. *Eur Neurol* 2014; 71: 271-279.
- 275 Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Gomez Cano M, McManus D, Mallik S, Hobart J, CUPID investigator group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. *Lancet Neurol*. 2013; 12: 857-865.
- 276 Strupp M. Multiple sclerosis II: new diagnostic criteria, association with smoking and effects of cannabis on cognitive function. *J Neurol*. 2011 May; 258(5): 954-7. doi: 10.1007/s00415-011-6049-2.
- 277 Greenberg HS, Werness SA, Pugh JE, Andrus RO, Anderson DJ, Domino EF. Short-term effects of smoking cannabis on balance in patients with multiple sclerosis and normal volunteers. *Clin Pharmacol Ther*. 1994 Mar; 55(3): 324-8.
- 278 Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ*. 2012 Jul 10; 184(10): 1143-50.
- 279 Killestein J, Hoogervorst EL, Reif M, Kalkers NF, Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. *Neurology*. 2002 May 14; 58(9): 1404-7.
- 280 Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 2004; 35: 38-45.
- 281 Abrams DI. Potential interventions for HIV/AIDS wasting: an overview. *Journal of Acquired Immune Deficiency Syndromes: JAIDS*. 2000; 25(Suppl 1): S74-S80.
- 282 Edelman EJ, Tetrault JM, Fiellin DA. Substance use in older HIV-infected patients. *Curr Opin HIV AIDS*. 2014 Jul; 9(4): 317-24.
- 283 Attonito JM, Dévieux JG, Lerner BD, Hospital MM, Rosenberg R. Exploring Substance Use and HIV Treatment Factors Associated with Neurocognitive Impairment among People Living with HIV/AIDS. *Front Public Health*. 2014 Aug 11; 2: 105.
- 284 Parsons JT, Starks TJ, Millar BM, Boonrai K, Marcotte D. Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence. *Drug Alcohol Depend*. 2014 Jun 1; 139: 33-40.
- 285 Andrae MH, Carter GM, Shaparin N, Suslov K, Ellis RJ, Ware MA, Abrams DI, Prasad H, Wilsey B, Indyk D, Johnson M, Sacks HS. Inhaled cannabis for chronic neuropathic pain: an individual patient data meta-analysis. *J Pain*. 2015 Sep 8. pii: S1526-5900(15)00812-3.. [Epub ahead of print]
- 286 Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Br J Clin Pharmacol*. 2011 Nov; 72(5): 735-44.
- 287 Hill KP. Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review. *JAMA*. 2015 Jun 23-30; 313(24): 2474-83.
- 288 Hancock-Allen JB, Barker L, VanDyke M, Holmes DB. Notes from the Field: Death Following Ingestion of an Edible Marijuana Product--Colorado, March 2014. *MMWR Morb Mortal Wkly Rep*. 2015 Jul 24; 64(28): 771-2.
- 289 Hudak M, Severn D, Nordstrom K. Edible Cannabis-Induced Psychosis: Intoxication and Beyond. *Am J Psychiatry*. 2015 Sep 1; 172(9): 911-2.
- 290 Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. *Pharmacotherapy*. 2013 Feb; 33(2): 195-209.
- 291 Favrat B, Ménétrey A, Augsburger M, Rothuizen LE, Appenzeller M, Buclin T, Pin M, Mangin P, Giroud C. Two cases of "cannabis acute psychosis" following the administration of oral cannabis. *BMC Psychiatry*. 2005 Apr 1; 5: 17.

- 
- 292 Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. *J Pain*. 2015 Jul; 16(7): 616-27.
- 293 Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ*. 2010 Oct 5; 182(14): E694-701.
- 294 Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology*. 2007 Feb 13; 68(7): 515-21.
- 295 Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, Fishman S. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. *J Pain*. 2008 Jun; 9(6): 506-21.
- 296 Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. *J Pain*. 2013 Feb; 14(2): 136-48.
- 297 Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci U S A*. 2012; 109(40): E2657-E2664
- 298 Ellis RJ, Toperoff W, Vaida F, van den Brande G, Gonzales J, Gouaux B, Bentley H, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. *Neuropsychopharmacology*. 2009 Feb; 34(3): 672-80.
- 299 Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, Gamsa A, Bennett GJ, Collet JP. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ*. 2010 Oct 5; 182(14): E694-701.
- 300 Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. *J Pain Palliat Care Pharmacother*. 2014 Sep; 28(3): 216-25.
- 301 National Institute of Neurological Disorders and Stroke Alzheimer's Disease Information Page. Bethesda, National Institutes of Health, 2015 (<http://www.ninds.nih.gov/disorders/alzheimersdisease/alzheimersdisease.htm>, accessed 11 December 2015).
- 302 Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia. *Cochrane Database Syst Rev*. 2009 Apr 15; (2): CD007204.
- 303 Ahmed A, van der Marck MA, van den Elsen G, Olde Rikkert M. Cannabinoids in late-onset Alzheimer's disease. *Clin Pharmacol Ther*. 2015 Jun; 97(6): 597-606.
- 304 McLachlan RS. Marijuana: a time-honored but untested treatment for epilepsy. *Can J Neurol Sci*. 2015 Mar; 42(2): 88-91.
- 305 Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D. Systematic review: efficacy and safety of medical cannabis in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2014 Apr 29; 82(17): 1556-63. PMID: PMC4011465.
- 306 Lotan I, Treves TA, Roditi Y, Djaldetti R. Cannabis (medical cannabis) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. *Clin Neuropharmacol*. 2014 Mar-Apr; 37(2): 41-4. PMID: 24614667.
- 307 Kluger B, Triolo P, Jones W, Jankovic J. The therapeutic potential of cannabinoids for movement disorders. *Mov Disord*. 2015 Mar; 30(3): 313-27.
- 308 Lutge EE, Gray A, Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. *Cochrane Database Syst Rev*. 2013 Apr 30; 4: CD005175. doi: 10.1002/14651858.CD005175.pub3.
- 309 Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, et al. Short-term effects of cannabinoids in patients with HIV-1 infection: randomised, placebo controlled trial. *Annals of Internal Medicine* 2003; 139: 258-66.
- 310 Haney M, Rabkin J, Gunderson E, Foltin RW. Dronabinol and marijuana in HIV+ marijuana smokers: acute effects on caloric intake and mood. *Psychopharmacology* 2005; 181: 170-8.
- 311 Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric intake, Mood and Sleep. *Journal of Acquired Immune Deficiency Syndromes* 2007; 45: 545-554.
- 312 Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidtkoer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA*. 2015 Jun 23-30; 313(24): 2456-73.
- 313 Abrams DI, Guzman M. Cannabis in cancer care. *Clin Pharmacol Ther*. 2015 Jun; 97(6): 575-86.
- 314 Cannabis and Cannabinoids—for health professionals (PDQ®). Bethesda, National Cancer Institute, 2015 ([http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq#section/\\_15](http://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq#section/_15), accessed 11 December 2015).
- 315 Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. *Br J Pharmacol*. 2011 Aug; 163(7): 1411-22.



- 
- 316 Kalant H. Smoked marijuana as medicine: not much future. *Clin Pharmacol Ther.* 2008 Apr; 83(4): 517-9.
- 317 Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA. Cannabidiol, a non-psychoactive component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. *Br J Pharmacol.* 2012 Apr; 165(8): 2620-34.
- 318 Joy, J.E., Watson, S.J., Jr., & Benson, J.A., Jr., eds. *Marijuana and Medicine: Assessing Science Base* (National Academies Press, Washington, DC, 1999).
- 319 Lu ML, Agito MD. Cannabinoid hyperemesis syndrome: Marijuana is both antiemetic and proemetic. *Cleve Clin J Med.* 2015 Jul; 82(7): 429-34.
- 320 Sun S, Zimmermann AE. Cannabinoid hyperemesis syndrome. *Hosp Pharm.* 2013; 48: 650-5. 129.
- 321 Cathcart P, de Giorgio A, Stebbing J. Cannabis and cancer: reality or pipe dream? *Lancet Oncol.* 2015 Oct; 16(13): 1291-2.
- 322 Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S, Schmidtkoer S, Westwood M, Kleijnen J. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. *JAMA.* 2015 Jun 23-30; 313(24): 2456-73.
- 323 Guzmán M, Duarte MJ, Blázquez C, Ravina J, Rosa MC, Galve-Roperh I, Sánchez C, Velasco G, González-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. *Br J Cancer.* 2006 Jul 17; 95(2): 197-203.
- 324 Weiss A, Friedenberg F. Patterns of cannabis use in patients with Inflammatory Bowel Disease: A population based analysis. *Drug Alcohol Depend.* 2015 Sep 14. [Epub ahead of print]
- 325 Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. *Clin Gastroenterol Hepatol.* 2013 Oct; 11(10): 1276-1280.
- 326 Manhapra A, Stefanovics E, Rosenheck R. Treatment outcomes for veterans with PTSD and substance use: Impact of specific substances and achievement of abstinence. *Drug Alcohol Depend.* 2015 Sep 25. pii: S0376-8716(15)01664-6. [Epub ahead of print]
- 327 Wilkinson ST, Stefanovics E, Rosenheck RA. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. *J Clin Psychiatry.* 2015 Sep; 76(9): 1174-80.
- 328 Sun X, Xu CS, Chadha N, Chen A, Liu J. Marijuana for Glaucoma: A Recipe for Disaster or Treatment? *Yale J Biol Med.* 2015 Sep 3; 88(3): 265-9.
- 329 Merritt JC, Crawford WJ, Alexander PC, Anduze AL, Gelbart SS. Effect of marijuana on intraocular and blood pressure in glaucoma. *Ophthalmology.* 1980; 87(3): 222-8.
- 330 Chien FY, Wang R, Mittag TW, Podos SM. Effect of WIN55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. *Arch Ophthalmol.* 2003; 121(1): 87-90.
- 331 Hepler RS, Frank IR. Marijuana smoking and intraocular pressure. *JAMA.* 1971; 217(10): 1392.
- 332 Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. *J Glaucoma.* 2006; 15(5): 349-53.
- 333 Flach AJ. Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. *Trans Am Ophthalmol Soc.* 2002; 100: 215-22.
- 334 Nucci C, Bari M, Spano A, Corasaniti M, Bagetta G, Maccarrone M, et al. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. *Prog Brain Res.* 2008; 173: 451-64.
- 335 Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. *J Glaucoma.* 2006; 15(5): 349-353.